

From: Russell White <whiter@api.org>
Sent: Tuesday, August 14, 2007 6:43 PM (GMT)
To: BenzConsort-OC@listserve.api.org
Cc: BenzConsort-TC@listserve.api.org; BHRC Communications Committee <benzconsort-cc@listserve.api.org>
Subject: Shanghai Health Study - 2Q budget
Attach: BHRC Program Expenses 2Q07 rpt - DRAFT.xls

Oversight Committee,

Attached is the Shanghai Health Study budget through the second quarter of 2007. It reflects the new contracts with BHRC member companies, Cinpathogen, and the University of Colorado. The budget subteam looked it over last week. If you have comments or questions please contact me. I can make any corrections necessary before the next scheduled OC call on September 13.

<<BHRC Program Expenses 2Q07 rpt - DRAFT.xls>>

Russell White

Regulatory and Scientific Affairs
American Petroleum Institute
1220 L Street NW
Washington, DC 20005-4070

Tel: 202-682-8344

Fax: 202-682-8270

Benzene Health Research Consortium
2Q07 Financial Report Overview

	A	B	C	D	E	F	G	H	I	J	K	L	M
1													
2													
3	EXPENSE DISCUSSION:											DRAFT	
4	Fund Balance at API 2Q07:				\$ 5,040,459								
5	Fund Balance in spreadsheet 2Q07:				\$ 5,040,458								
6													
7													
8													
9	Irons Field Expenses: No funds disbursed in 2Q07 because of high balance unspent.												
10	UCHSC: \$0 disbursed in 2Q07												
11	AHS: \$173,693 spent in 2Q07												
12	Fudan University: No activity												
13	SRP/ERP: \$7,875 spent in 2Q07.												
14	Communications: No activity in 2Q07												
15	Outside Legal Council: \$24,224 spent in 2Q07 (Budget increased \$40,000 from contingency.)												
16	QA/QC: \$5,190 spent in 2Q07												
17	Contingency: \$1,414,201 remains uncommitted												
18	API Administrative Costs: \$37,472 spent in 2Q07												
19	Revenue: \$3,166,408 in 2Q07 (\$3,119,412 Sponsor payments; \$46,996 Interest income)												
20													
21													
22	<u>FORWARD GUIDANCE:</u>												
23	<u>Executive Summary:</u>												
24													
25													
26													
27	Technical Budget Work Group Acceptance:												
28	Oversight Committee Acceptance:												
29	Posted to Website:												
30													
31													
32	LT 8/24/05												
33	BJ 11/29/05												
34	RDW 6/1/07												
35	RT 8/1/2007												

Benzene Health Research Consortium
Approved Program Budget
2Q07 Financial Report

	A	B	C	D	E
1			Original Cost	Approved	Unapproved
2	Item		Estimate (Jan. 2001)	Revised Cost Estimate (Dec. 2001)	Changes not approved (June 2003)
3	AHSciences Case-Control Study		1,595,000	2,283,095	2,283,095
4	DP & ME Studies (UCHSC)		13,665,017	15,258,017	15,258,000
5	Irons(T & E)		1,253,428	1,253,428	1,597,273
6	Fudan University		165,700	190,555	661,000
7	Cinpathogen		-	-	-
8	Total Research Costs		16,679,145	18,985,095	19,799,368
9	Scientific Review Panel			648,000	551,736
10	Ethics Review Panel			216,000	192,000
11	External Pathology & Cytogenetics Workgroups(Cost in UC cost)			130,000	-
12	Exposure Assessment				
13	Total Panel Costs		450,000	994,000	743,736
14	API Seed Monies		500,000	-	-
15	Outside Counsel			500,000	100,576
16	Communications		1,000,000	1,000,000	960,600
17	QA/QC Activities			225,000	100,000
18	UCHSC Interest				
19	Committed funds				
20	Contingency		190,855	-	-
21	Miscellaneous Costs		1,690,855	1,725,000	1,161,176
22	Subtotal		18,820,000	21,704,095	21,704,280
23	API Admin.		941,000	1,085,205	1,085,019
24	GRAND TOTAL		\$ 19,761,000	\$ 22,789,300	\$ 22,789,299
25	Cummulative Interest Earned				
26					
27	Notes by API				
28	Notes/Assumptions for Dec. 2001 revised budget:				
29		- The total research costs have changed as a result of the - Panel costs assume that there will be only one face-to-face meeting for each panel each year.			
30					
31					
32					
33					
34	LT 7/24/05				
35	RDW 7/27/06				
36	rdw 10/19/06				
37	rdw 3/12/07				

Benzene Health Research Consortium
Approved Program Budget
2Q07 Financial Report

	F	G	H	I	J	K	L	M
1	Approved	Approved	Approved	Approved	Approved	Approved	Approved	Approved
2	11 NOV 03 OC mtg	21 APR 04 OC mtg	16 Dec 04 OC mtg	3 May 05 OC mtg	21 Aug 06 OC mtg	20 Sept 06 OC mtg	08 March 07 OC mtg	21-Jun-07
3	2,283,095	2,283,095	2,283,095	2,930,841	2,930,841	2,930,841	2,930,841	3,819,119
4	14,508,000	14,508,000	14,508,000	18,332,769	18,332,769	18,332,769	18,332,769	20,045,469
5	1,413,428	1,413,428	1,413,428	1,413,428	1,413,428	1,413,428	1,413,428	1,413,428
6	230,000	230,000	230,000	306,062	306,062	379,829	379,829	444,829
7	-	-	-	-	-	-	-	4,847,740
8	18,434,523	18,434,523	18,434,523	22,983,100	22,983,100	23,056,867	23,056,867	30,570,585
9	300,000	300,000	300,000	300,000	346,950	346,950	346,950	446,950
10	64,000	64,000	64,000	64,000	126,192	126,192	126,192	166,192
11	-	-	-	-	-	-	-	-
12					109,000	109,000	109,000	109,000
13	364,000	364,000	364,000	364,000	582,142	582,142	582,142	722,142
14	-	-	-	-	-	-	-	-
15	100,000	100,000	100,000	140,000	140,000	140,000	180,000	245,000
16	550,000	550,000	300,000	300,000	300,000	300,000	300,000	500,000
17	100,000	100,000	50,000	50,000	50,000	50,000	50,000	200,000
18	(100,000)	-	-	-	-	-	-	-
19				156,391	156,391	156,391	156,391	156,391
20	390,272	290,272	590,272	694,304	476,162	402,395	362,395	1,227,395
21	1,040,272	1,040,272	1,040,272	1,340,695	1,122,553	1,048,786	1,048,786	2,328,786
22	19,838,795	19,838,795	19,838,795	24,687,795	24,687,795	24,687,795	24,687,795	33,621,513
23	1,245,205	1,245,205	1,245,205	1,445,205	1,445,205	1,445,205	1,445,205	1,609,629
24	\$ 21,084,000	\$ 21,084,000	\$ 21,084,000	\$ 26,133,000	\$ 26,133,000	\$ 26,133,000	\$ 26,133,000	\$ 35,231,142
25					208,347	240,121	296,202	343,198
26								
27								
28	3 May 05 revised budget notes							
29	- \$423 added to contingency to round total budget to nearest thousand							
30	- increased API administrative costs for one extra year (2007)							
31								
32								
33								
34								
35								
36								
37								

Benzene Health Research Consortium
Executive Summary
2Q07 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N
1														
2														
3			Actuals			ACTUALS							PROJECTED	
4			Inception											
5			Thru	Actuals	Actuals	ACTUALS	ACTUALS			PROJECTED			PROJECTED	
6			December	Jan - Dec	Jan - Dec	Jan - June	Program			2007			2007	
7	Cost Centers	Project #	2004	2005	2006	2007	to Date			Jan - June			Jan - Dec	
8														
9	Income		\$ 16,765,693	\$ 5,206,657	\$ 6,938,163	\$ 3,166,408	\$ 32,076,921			\$ -			\$ 4,226,212	
10														
11	Cost Centers													
12	UCHSC*	X8105	10,137,850	3,624,030	4,000,000	570,889	18,332,769	13,778,460		570,889			1,570,889	
13	Irons-Field Expense*	X8106	788,486	262,000	262,000	55,000	1,367,486	990,282		100,942			100,942	
14	Applied Health Sciences	X8107	1,391,014	548,720	558,214	286,252	2,784,201			320,584			641,168	
15	Fudan University	X8108	124,090	4,007	76,377	-	204,474			-			99,995	
16	Scientific & Ethics Panels	X8109	181,713	76,176	95,418	11,850	365,158			9,000			96,726	
17	Communications	X8103	294,161	-	-	-	294,161			-			1,946	
18	Outside Legal Counsel	X8104	64,529	33,706	39,154	38,115	175,505			35,622			71,242	
19	QA/QC Support	X8110	-	-	1,202	5,246	6,448			54,292			100,000	
20	API Administrative	X8100	856,208	170,475	160,782	68,214	1,255,679			94,000			225,450	
21	Exposure Assessment	x8111	-	-	12,324	21,322	33,646			60,000			69,000	
22	Cinpathogen	x8112			-	2,100,000	2,100,000			2,100,000			3,375,000	
23	Committed Contingency		104,473	51,918	-	-	156,391			-			-	
24	Uncommitted Contingency						-			-			-	
25	Total Expenses		\$ 13,942,525	\$ 4,771,033	\$ 5,205,472	\$ 3,156,888	\$ 27,075,918			\$ 3,345,329			\$ 6,352,358	
26														
27	Fund Balance		\$ 2,823,169	\$ 3,298,247	\$ 5,030,938	\$ 9,520	\$ 5,040,458							
28														
29														
30	blue is projected fund balanced to project													
31	* amount disbursed by API													
32														
33														
34														
35														
36														
37	LT 8/3/05	DRAFT												
38	RW 2/20/06													
39	RT 7/19/06													
40	rdw 10/19/06													
41														
42														
43														

sponsors	
MAP contrib.	
API interest	
UCHSC interest	
TOTAL	
Uncomr	
contin & interest	
spent as of 2Q07	
Remaining	

Benzene Health Research Consortium
Executive Summary
2Q07 Financial Report

	O	P	Q	R
1				
2				
3				BUDGET
4				
5	PROJECTED		PROJECTED	
6	2008		End of	Program
7	Jan - Dec		Project	Budget
8			Income	
9	\$ 2,457,615		35,609,340	\$ 35,231,142
10				
11			Expenses	
12	712,700		20,045,469	20,045,469
13	-		1,367,486	1,413,428
14	703,504		3,808,289	3,819,119
15	45,441		349,910	444,829
16	140,000		592,884	613,142
17	200,000		496,107	500,000
18	33,875		245,000	245,000
19	100,000		152,156	200,000
20	164,424		1,551,553	1,609,629
21	-		42,646	109,000
22	1,472,740		4,847,740	4,847,740
23	-		156,391	156,391
24	-		1,414,201	1,227,395
25	\$ 3,572,684		\$ 35,069,832	\$ 35,231,142
26				
27			\$ 539,507	
28				
29				
30				
31				
32	Income Detail			
33			31,518,724	
34			\$215,000	
35			266,996	
36			76,202	
37				
38			\$32,076,921	
39				
40	Uncommitted Contingency			
41			1,570,593	
42			156,391	
43			1,414,201	

Benzene Health Research Consortium
Cash Flow Statement 2Q07 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
1		2000	2001	2002		2003				2004				2005				2006
2		1st - 4th Qtr.	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.
3	INCOME																	
4	Income for Reporting Period	60,246	2,113,132	8,367,446	448,024	3,186	4,265,241	1,485,975	6,746	6,506	9,292	1,096,000	372,143	3,009,787	728,727	-	1,934,291	31,774
5	Income, Cumulative	60,246	2,173,378	10,540,824	10,988,848	10,992,034	15,257,275	16,743,149	16,749,895	16,756,401	16,765,693	17,861,693	18,233,836	21,243,623	21,972,350	21,972,350	23,906,641	23,938,415
6	EXPENSE																	
7	Actual Expenses	24,600	1,577,811	7,652,678	318,759	258,097	310,244	66,019	1,348,626	1,047,131	1,338,560	247,035	1,063,761	318,580	3,102,202	156,494	2,527,048	327,707
8	Expense, Cumulative	24,600	1,602,411	9,255,088	9,573,847	9,831,945	10,142,189	10,208,207	11,556,834	12,603,965	13,942,525	14,189,560	15,253,321	15,571,901	18,674,103	18,830,597	21,357,645	21,685,352
9	INCOME LESS EXPENSE																	
10	Reporting Period	35,646	535,321	714,768	129,265	(254,911)	3,954,997	1,419,856	(1,341,880)	(1,040,625)	(1,329,268)	848,965	(691,618)	2,691,207	(2,373,475)	(156,494)	(592,757)	(295,933)
11	Cumulative	35,646	570,967	1,285,736	1,415,001	1,160,089	5,115,086	6,534,942	5,193,061	4,152,436	2,823,169	3,672,133	2,980,515	5,671,722	3,298,247	3,141,753	2,548,996	2,253,064
12																		
13		NOTE:	2,548,996	in bank at API														
14	blue designates projected income or expense			This number does not agree with the executive summary because it is based on actuals, not disbursed funds.								\$372,143						
15																		
16	LT 8/23/05	DRAFT																
17	RT 7/19/06																	

Benzene Health Research Consortium
Cash Flow Statement 2Q07 Financial Report

	S	T	U	V	W	X
1	2007					TOTALS
2	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3						
4	4,972,098	-	3,166,408	1,039,804	20,000	33,136,725
5	28,910,513	28,910,513	32,076,921	33,116,725	33,136,725	
6						
7	2,205,983	165,806	2,365,193	-	-	26,422,334
8	23,891,335	24,057,141	26,422,334	26,422,334	26,422,334	
9						
10	2,766,115	(165,806)	801,215	1,039,804	20,000	
11	5,019,179	4,853,373	5,654,588	6,694,392	6,714,392	
12						
13						
14						
15						
16						
17						

Benzene Health Research Consortium
Program Expense Summary 2Q07 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N
		2000	2001	2002	2003					2004			2005	
	Cost Centers	1st - 4th Qtr.	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.
1														
2	UCHSC													
3	Disbursed		1,225,000	6,339,598	-	-	(48,839)	-	874,031	874,030	874,030	-	874,030	-
4	Budgeted	-	648,390	3,969,140	1,230,711	-	2,039,466	-	827,532	-	827,532	-	1,940,413	-
5	Actual expense	-	523,807	3,248,834	1,717,169	-	553,672	-	2,045,114	-	1,535,622	-	1,787,329	-
6	Current/Variance	-	124,583	720,306	(486,458)	-	1,485,794	-	(1,217,582)	-	(708,090)	-	153,084	-
7	Cumm Variance	-	124,583	844,889	332,137	332,137	1,813,804	1,813,804	586,386	586,386	(131,540)	(131,540)	140,914	140,914
8	Irons - Field Expenses													
9	Disbursed		145,763	393,723	-	-	-	-	189,320	-	59,680	131,000	-	131,000
10	Budgeted	-	3,200	259,060	138,359	69,179	55,508	55,508	55,508	55,508	55,508	55,508	55,508	55,508
11	Actual expense	-	3,157	195,549	89,577	54,382	169,606	43,945	95,409	49,390	60,427	-	110,927	56,038
12	Current/Variance	-	43	63,511	48,782	14,797	(114,098)	11,563	(39,901)	6,118	(4,919)	55,508	(55,419)	(530)
13	Cumm Variance	-	43	63,554	112,336	127,133	13,035	24,598	(15,303)	(9,185)	(14,104)	41,404	(14,015)	(14,545)
14	Applied Health Sciences													
15	Budgeted	-	84,025	435,513	216,256	108,128	108,128	98,340	98,340	98,340	98,340	110,467	203,034	133,792
16	Actual expense	-	136,329	435,406	140,665	149,389	90,103	-	168,623	105,508	164,991	70,316	123,114	132,925
17	Current/Variance	-	(52,304)	107	75,591	(41,261)	18,025	98,340	(70,283)	(7,168)	(66,651)	40,151	79,920	967
18	Cumm Variance	-	(52,304)	(52,197)	23,394	(17,868)	157	98,497	28,215	21,047	(45,604)	(5,454)	79,920	80,787
19	Fudan University - Case/Control Study													
20	Budgeted	-	31,303	42,751	21,376	10,688	7,288	7,288	7,288	7,288	7,287	-	40,281	-
21	Actual expense	-	-	15,470	6,492	8,851	1,168	-	27,755	-	64,354	-	-	-
22	Current/Variance	-	31,303	27,281	14,883	1,837	6,120	7,288	(20,467)	7,288	(57,067)	-	40,281	-
23	Cumm Variance	-	31,303	58,584	73,467	75,305	81,425	88,713	68,246	75,534	18,467	18,467	40,281	40,281
24	Scientific & Ethics Panels/cyto wkshop													
25	Budgeted	-	30,240	120,960	60,480	30,240	4,508	(163,074)	3,000	4,750	72,000	1,500	1,000	4,250
26	Actual expense	-	18,673	5,122	9,994	16,984	32,081	500	12,029	2,500	83,830	-	2,500	14,016
27	Current/Variance	-	11,567	115,838	50,486	13,256	(27,573)	(163,574)	(9,029)	2,250	(11,830)	1,500	(1,500)	(9,766)
28	Cumm Variance	-	11,567	127,405	177,891	191,147	163,574	-	(9,029)	(6,779)	(18,609)	(17,109)	(18,609)	(28,375)
29	Communications - APCO													
30	Budgeted	-	60,000	240,000	125,000	62,500	(196,636)	15,001	15,000	15,000	(41,704)	-	-	-
31	Actual expense	-	-	240,738	14,564	7,877	27,688	-	790	1,235	1,270	-	-	-
32	Current/Variance	-	60,000	(738)	110,436	54,623	(224,324)	15,001	14,210	13,765	(42,974)	-	-	-
33	Cumm Variance	-	60,000	59,262	169,699	224,322	(2)	14,999	29,209	42,974	0	0	0	0
34	Outside Legal Counsel													
35	Budgeted	-	30,000	120,000	62,500	31,250	(210,542)	4,175	4,175	4,175	4,175	4,175	7,811	7,811
36	Actual expense	-	-	13,565	1,728	-	17,915	365	2,995	1,870	26,092	4,827	16,769	-
37	Current/Variance	-	30,000	106,435	60,772	31,250	(228,457)	3,810	1,180	2,305	(21,918)	(653)	(8,958)	7,811
38	Cumm Variance	-	30,000	136,435	197,207	228,457	0	3,810	4,990	7,284	(14,623)	(15,276)	(8,958)	(1,147)
39	QA/QC Support													
40	Budgeted	-	13,500	54,000	28,126	14,063	(109,689)	6,250	6,250	6,250	(18,750)	4,167	4,167	4,167
41	Actual expense	-	-	-	-	-	-	-	-	-	-	-	-	-
42	Current/Variance	-	13,500	54,000	28,126	14,063	(109,689)	6,250	6,250	6,250	(18,750)	4,167	4,167	4,167
43	Cumm Variance	-	13,500	67,500	95,626	109,689	-	6,250	12,500	18,750	-	4,167	8,333	12,500
44	Exposure Assessment													
45	Budgeted	-	-	-	-	-	-	-	-	-	-	-	-	-
46	Actual expense	-	-	-	-	-	-	-	-	-	-	-	-	-
47	Current/Variance	-	-	-	-	-	-	-	-	-	-	-	-	-
48	Cumm Variance	-	-	-	-	-	-	-	-	-	-	-	-	-
49	Cinpathogen													
50	Budgeted	-	-	-	-	-	-	-	-	-	-	-	-	-
51	Actual expense	-	-	-	-	-	-	-	-	-	-	-	-	-
52	Current/Variance	-	-	-	-	-	-	-	-	-	-	-	-	-
53	Cumm Variance	-	-	-	-	-	-	-	-	-	-	-	-	-
54	Contingency Funds													
55	Budgeted	-	-	-	-	-	-	-	-	-	-	-	-	-
56	Actual expense	-	-	-	-	-	101,473	-	-	-	3,000	3,496	7,480	-
57	exp/committ	-	-	-	-	-	101,473	-	-	-	3,000	50,296	7,480	-
58	uncommitted	-	-	-	-	-	-	-	-	-	-	-	-	-
59	API Administrative and Overhead													
60	Budgeted	-	65,113	260,448	135,654	67,826	75,934	66,700	66,700	72,700	64,400	29,280	48,500	39,500
61	Actual expense	24,600	62,046	209,056	145,318	74,997	88,655	65,154	73,084	61,988	61,312	37,396	39,068	40,639
62	Current/Variance	(24,600)	13,067	51,392	(9,662)	(7,171)	(12,721)	1,546	(6,384)	10,712	(11,854)	(8,116)	8,632	(1,139)
63	Cumm Variance	(24,600)	(11,533)	39,859	30,197	23,026	10,305	11,851	5,467	16,179	4,325	(3,791)	8,632	7,493
64	TOTALS	2000	2001	2002	2003					2004		2005		
65	Budgeted	-	965,771	5,501,872	2,018,461	393,874	1,773,965	90,188	1,083,793	264,011	1,068,788	205,096	2,300,714	245,027
66	Actual expense	24,600	734,012	4,363,739	2,125,505	312,479	1,082,361	109,964	2,425,798	222,491	2,000,899	116,035	2,087,987	243,618
67	Current/Variance	(24,600)	231,759	1,138,133	(107,044)	81,394	691,604	(19,776)	(1,342,006)	41,520	(932,111)	89,061	212,727	1,409
68	Cumm Variance	(24,600)	207,159	1,345,292	1,238,248	1,319,642	2,011,246	1,991,470	649,464	690,984	(241,127)	(152,066)	60,660	62,070
69	CUMULATIVE TOTALS	2000	2001	2002	2003					2004		2005		
70	Budgeted	-	965,771	6,467,643	8,486,104	8,879,977	10,653,942	10,744,130	11,827,923	12,091,933	13,160,721	13,365,817	15,666,531	15,911,558
71	Expense	24,600	758,612	5,122,351	7,247,856	7,560,335	8,642,696	8,752,660	11,178,458	11,400,949	13,401,848	13,517,883	15,605,870	15,849,488
72	Variance	(24,600)	207,159	1,345,292	1,238,248	1,319,642	2,011,246	1,991,470	649,464	690,984	(241,127)	(152,066)	60,660	62,070
73	Blue: future cumulative variance has no meaning until Expense entered.						\$21,078,410							
74	LT 8/3/05	DRAFT			API disbursed		21,314,021							
75	RT 7/19/06	Amt. At UCHSC & Irons Field exp. Bank acct					(\$235,610)							69,235
76														
77														
78														
79														
80	API disbursed by period	24,600	1,577,811	7,652,678	318,759	258,097	310,244	66,019	1,348,626	1,047,131	1,338,560	247,035	1,063,761	318,580
81	(includes pre-payments													
82	for UCHSC & Irons Field)													

**Benzene Health Research Consortium
Program Expense Summary 2Q07 Financial Report**

	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA	AB
1	2006				2007				2008				TOTALS	
2	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3														
4	2,750,000	-	2,000,000	-	2,000,000	570,889	-		-					18,332,769
5	1,940,413	-	1,906,001	-	1,906,001	570,889		1,000,000			712,000			19,518,488
6	2,366,913	-	2,288,332	-	1,863,525	-	-	-	-					17,940,317
7	(426,500)	-	(392,331)	-	42,476	-	507,861		507,862					507,862
8	(297,756)	(297,756)	(701,049)	(701,049)	(669,655)	(669,655)	(165,855)	(165,855)	337,946					392,452
9														
10	-	131,000	-	-	131,000	-	55,000	-	-					1,367,486
11	55,508	55,508	55,508	55,507	55,507	55,507	55,507	55,507	55,507					1,413,428
12	61,875	43,488	68,415	-	-	-	-	-	-					1,102,184
13	(6,367)	12,020	(12,907)	55,507	55,507	55,507	55,507	55,507	55,507					89,216
14	(20,912)	(8,891)	(21,798)	33,709	89,216	144,723	200,230	255,737	311,244					311,244
15														
16	133,792	136,988	136,988	136,988	136,988	160,292	160,292	160,292	160,292	175,876	175,876	175,876	175,876	3,819,119
17	222,365	73,855	111,422	141,140	231,797	112,560	173,692	-	-					2,784,201
18	(88,573)	63,133	25,566	(4,152)	(94,809)	47,732	(13,400)	160,292	160,292					160,292
19	(7,787)	55,347	80,913	76,761	(18,048)	29,684	16,284	176,576	336,868					1,034,919
20														
21	40,282	-	47,236	-	47,236	-	50,000	-	50,000					439,126
22	4,007	-	-	76,377	-	-	-	-	-					204,474
23	36,275	-	47,236	(76,377)	47,236	-	50,000	-	50,000					50,000
24	76,556	76,556	123,792	47,415	94,651	94,651	144,651	144,651	194,651					234,651
25														
26	70,000	3,823	1,000	83,226	4,500	4,500	4,500	83,226	4,500					473,143
27	59,660	2,800	4,800	58,047	29,771	3,975	7,875	-	-					365,158
28	10,340	1,023	(3,800)	25,179	(25,271)	525	(3,375)	83,226	4,500					4,500
29	(18,035)	(17,012)	(20,812)	4,367	(20,905)	(20,380)	(23,755)	59,471	63,971					63,971
30														
31	1,946	-	-	-	1,946	-	-	-	1,946					300,000
32	-	-	-	-	-	-	-	-	-					294,161
33	1,946	-	-	-	1,946	-	-	-	1,946					3,893
34	1,946	1,946	1,946	1,946	3,893	3,893	3,893	3,893	5,839					5,839
35														
36	7,811	7,811	7,811	7,811	7,811	17,811	17,811	17,810	17,810					180,000
37	12,110	5,776	6,084	1,848	25,448	13,891	24,224	-	-					175,505
38	(4,299)	2,035	1,727	5,965	(17,637)	3,920	(6,413)	17,810	17,810					4,495
39	(5,446)	(3,411)	(1,684)	4,281	(13,356)	(9,436)	(15,849)	1,961	19,771					4,495
40														
41	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167					50,000
42	-	-	-	-	1,202	56	5,190	-	-					6,448
43	4,167	4,167	4,167	4,167	2,964	4,111	(1,023)	4,167	4,167					43,552
44	16,667	20,833	25,000	29,167	32,131	36,242	35,219	39,385	43,552					43,552
45														
46	-	-	-	-	40,000	30,000	30,000	9,000	-					109,000
47	-	-	-	-	12,324	4,583	16,739	-	-					33,646
48	-	-	-	-	27,676	25,417	13,261	9,000	-					75,354
49	-	-	-	-	27,676	53,093	66,354	75,354	75,354					75,354
50														
51	-	-	-	-	-	-	2,100,000	-	1,275,000					3,375,000
52	-	-	-	-	-	-	2,100,000	-	-					2,100,000
53	-	-	-	-	-	-	-	-	1,275,000					1,275,000
54	-	-	-	-	-	-	-	-	1,275,000					1,275,000
55														
56	-	-	-	-	-	-	-	-	-					850,695
57	1,200	-	-	-	-	-	-	-	-					116,649
58	288	-	-	-	-	-	-	-	-					162,537
59	-	-	-	-	-	-	-	-	-					688,158
60														
61	63,500	40,500	35,000	46,000	42,000	47,000	47,000	72,000	59,450					1,445,205
62	52,572	30,576	37,995	50,296	41,916	30,741	37,472	-	-					923,832
63	10,928	9,924	(2,995)	(4,296)	84	16,259	9,528	72,000	59,450					450,028
64	18,421	28,345	25,351	21,054	21,139	37,397	46,925	118,925	178,375					178,375
65														
66	2,317,419	248,797	2,193,711	333,699	2,246,156	890,166	2,469,277	1,402,002	1,628,672					28,489,203
67	2,780,990	156,494	2,527,048	327,707	2,205,993	165,806	2,365,193	-	-					23,946,574
68	(463,571)	92,303	(333,337)	5,992	40,173	724,360	104,084	1,402,002	1,628,672					3,262,746
69	(401,502)	(309,199)	(642,536)	(636,544)	(596,371)	127,989	232,073	1,634,074	3,262,746					4,542,629
70														
71	18,228,977	18,477,774	20,671,485	21,005,184	23,251,340	24,141,505	26,610,782	28,012,784	29,641,456					28,489,203
72	18,630,479	18,786,972	21,314,021	21,641,727	23,847,710	24,013,516	26,378,710	26,378,710	26,378,710					26,378,710
73	(401,502)	(309,199)	(642,536)	(636,544)	(596,371)	127,989	232,073	1,634,074	3,262,746					2,110,494
74														
75														
76														
77														
78														
79														
80	3,102,202	244,006	2,160,301	327,707	2,473,458	736,695	2,420,193	0	0					24,604,328
81														
82														

**Benzene Health Research Consortium
UCHSC Grant 2Q07 Financial Report**

	A	B	C	D
1	UCHSC (x8105)	2001	2002	
2	Cost Centers	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.
3	Grant Payments			
4	Disbursed	1,225,000	6,339,598	-
5	Personnel			
6	Budgeted	172,140	573,160	331,316
7	Actual expense	172,140	714,688	314,703
8	Current/Variance	0	(141,528)	16,613
9	Cumm Variance	0	(141,528)	(124,915)
10	Operating Expenses			
11	Budgeted	13,131	378,462	198,373
12	Actual expense	12,177	301,522	158,850
13	Current/Variance	954	76,940	39,523
14	Cumm Variance	954	77,894	117,417
15	Subcontracts			
16	Budgeted	123,629	1,796,030	649,014
17	Actual expense	-	1,025,372	845,860
18	Current/Variance	123,629	769,658	(296,846)
19	Cumm Variance	123,629	893,287	596,441
20	Travel			
21	Budgeted	-	23,947	11,340
22	Actual expense	-	8,647	346
23	Current/Variance	-	15,300	10,994
24	Cumm Variance	-	15,300	26,294
25	Equipment			
26	Budgeted	291,568	919,645	-
27	Actual expense	291,568	899,642	274,508
28	Current/Variance	-	19,003	(274,508)
29	Cumm Variance	-	19,003	(255,505)
30	Indirect			
31	Budgeted	47,922	279,896	140,668
32	Actual expense	47,922	298,963	122,902
33	Current/Variance	(0)	(19,067)	17,766
34	Cumm Variance	(0)	(19,067)	(1,301)
35	TOTALS	2001	2002	
36	Budgeted	648,380	3,969,140	1,230,711
37	Actual expense	523,807	3,248,834	1,717,169
38	Current/Variance	124,583	720,306	(486,458)
39	Cumm Variance	124,583	844,889	332,137
40	CUMULATIVE TOTALS	2001	2002	
41	Budgeted	648,380	4,617,530	5,848,241
42	Expense	523,807	3,772,641	5,489,810
43	Variance	124,583	844,889	358,431
44				
45	Blue: future cumulative variance has no meaning until Expense entered.	Note: Actual expenses from Progress Report or UC Grants & Contracts Financials.		
46				
47	LT 8/02/05	Amt. paid UCHSC to date:		\$13,761,880
48	BJ 8/02/05	Amt. expensed to date:		\$13,778,460
49	RT 7/19/06	Amt. In UCHSC bank acct:		(\$16,580)
50	DRAFT			
51				

**Benzene Health Research Consortium
UCHSC Grant 2Q07 Financial Report**

	E	F	G	H	I
1	2003			2004	
2	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.
3					
4	-	(48,839)	-	874,031	874,030
5					
6	-	293,007	-	195,778	-
7	-	58,188	-	211,016	-
8	-	234,819	-	(15,238)	-
9	(124,915)	109,904	109,904	94,666	94,666
10					
11	-	259,003	-	195,773	-
12	-	150,857	-	364,542	-
13	-	108,346	-	(168,769)	-
14	117,417	225,763	225,763	56,994	56,994
15					
16	-	998,733	-	286,980	-
17	-	565,870	-	1,128,507	-
18	-	422,863	-	(841,517)	-
19	596,441	1,019,304	1,019,304	177,787	177,787
20					
21	-	4,127	-	9,836	-
22	-	-	-	-	-
23	-	4,127	-	9,836	-
24	26,294	30,421	30,421	40,257	40,257
25					
26	-	350,000	-	48,050	-
27	-	(274,568)	-	192,340	-
28	-	624,568	-	(144,290)	-
29	(255,505)	369,063	369,063	224,773	224,773
30					
31	-	144,596	-	91,105	-
32	-	53,525	-	148,709	-
33	-	91,071	-	(57,604)	-
34	(1,301)	89,770	89,770	32,166	32,166
35	2003			2004	
36	-	2,039,466	-	827,532	-
37	-	553,672	-	2,045,114	-
38	-	1,485,794	-	(1,217,582)	-
39	332,137	1,813,804	1,813,804	586,386	586,386
40	2003			2004	
41	5,848,241	7,897,707	7,897,707	8,715,239	8,715,239
42	5,489,810	6,043,482	6,043,482	8,088,596	8,088,596
43	358,431	1,844,225	1,844,225	626,643	626,643
44					
45				UCHSC statement error for travel, off by +\$105 (4Q03)	
46					
47	(Adjusted 4Q03: \$48,839 attributed to UCHSC in 3Q03 Report has been reallocated to Contingency: \$25,000 <i>pre-consortium grant in 2001</i> ; \$3,600 for IRB Review in 2002; \$20,239 for EMBSI "feasibility study" in 2002)				
48	(Adjusted 4Q03: 2001 costs had been double expensed in 2002 column; (-\$523,807) adjustment made in 4Q03)				
49					
50					
51					

Benzene Health Research Consortium
UCHSC Grant 2Q07 Financial Report

	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y
1			2005				2006				2007				2008	
2	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.
3																
4	874,030	-		874,030	-	2,750,000	-	2,000,000	-	2,000,000	570,889	-	1,000,000		712,700	
5																
6	195,778	-		219,087	-	219,087	-	199,472	-	199,472	-	73,107	-	73,107		
7	229,260	-		235,437	-	243,816	-	227,105	-	231,096	-	-	-	-		
8	(33,482)	-		(16,350)	-	(24,729)	-	(27,633)	-	(31,624)	-	73,107	-	73,107		
9	61,184	61,184		(16,350)	(16,350)	(41,079)	(41,079)	(69,712)	(69,712)	(100,336)	(100,336)	(27,229)	(27,229)	45,878		
10																
11	195,773	-		219,087	-	219,087	-	199,472	-	199,472	-	73,101	-	73,101		
12	237,258	-		104,457	-	227,940	-	267,828	-	245,256	-	-	-	-		
13	(41,485)	-		114,630	-	(8,853)	-	(68,356)	-	(45,784)	-	73,101	-	73,101		
14	15,509	15,509		114,630	114,630	105,777	105,777	37,421	37,421	(8,363)	(8,363)	64,738	64,738	137,839		
15																
16	286,990	-		1,331,839	-	1,331,839	-	1,351,912	-	1,351,912	-	304,797	-	304,798		
17	949,696	-		1,359,314	-	1,773,364	-	1,675,638	-	1,263,321	-	-	-	-		
18	(661,706)	-		(27,475)	-	(441,525)	-	(323,726)	-	89,591	-	304,797	-	304,798		
19	(483,919)	(483,919)		(27,475)	(27,475)	(469,000)	(469,000)	(792,726)	(792,726)	(704,135)	(704,135)	(399,338)	(399,338)	(94,540)		
20																
21	9,836	-		12,170	-	12,170	-	11,082	-	11,082	-	4,061	-	4,061		
22	-	-		-	-	-	-	120	-	-	-	-	-	-		
23	9,836	-		12,170	-	12,170	-	10,962	-	11,082	-	4,061	-	4,061		
24	50,093	50,093		12,170	12,170	24,340	24,340	35,302	35,302	46,384	46,384	50,445	50,445	54,506		
25																
26	48,050	-		54,772	-	54,772	-	49,868	-	49,868	-	18,275	-	18,275		
27	-	-		-	-	-	-	-	-	-	-	-	-	-		
28	48,050	-		54,772	-	54,772	-	49,868	-	49,868	-	18,275	-	18,275		
29	272,823	272,823		54,772	54,772	109,544	109,544	159,412	159,412	209,280	209,280	227,555	227,555	245,830		
30																
31	91,105	-		103,458	-	103,458	-	94,195	-	94,195	-	34,520	-	34,520		
32	120,408	-		98,121	-	121,793	-	127,641	-	123,952	-	-	-	-		
33	(29,303)	-		15,337	-	(19,335)	-	(33,446)	-	(29,657)	-	34,520	-	34,520		
34	2,863	2,863		15,337	15,337	(2,998)	(2,998)	(36,444)	(36,444)	(66,101)	(66,101)	(31,581)	(31,581)	2,939		
35			2005				2006				2007					
36	827,532	-	1,940,413	-	1,940,413	-	1,906,001	-	1,906,001	-	507,861	-	507,862			
37	1,535,622	-	1,797,329	-	2,366,913	-	2,298,332	-	1,863,525	-	-	-	-			
38	(708,090)	-	153,084	-	(426,500)	-	(392,331)	-	42,476	-	507,861	-	507,862			
39	(131,540)	(131,540)	140,914	140,914	(297,756)	(297,756)	(701,049)	(701,049)	(669,655)	(669,655)	(165,855)	(165,855)	337,946			
40			2005				2006				2007					
41	9,542,771	9,542,771	11,493,184	11,483,184	13,423,597	13,423,597	15,329,598	15,329,598	17,235,599	17,235,599	17,743,460	17,743,460	21,107,402			
42	9,624,218	9,624,218	11,411,547	11,411,547	13,778,480	13,778,480	16,076,782	16,076,782	17,940,317	17,940,317	17,940,317	17,940,317	17,940,317			
43	(81,447)	(81,447)	71,637	71,637	(354,863)	(354,863)	(747,194)	(747,194)	(704,718)	(704,718)	(196,857)	(196,857)	3,167,085			
44																
45																
46																
47																
48																
49																
50			2Q05 - variance adjusted to reflect only current qtr variance													
51			2Q05 - bedgeted expense projections revised per 3 May 05 revised program budget													

Benzene Health Research Consortium
UCHSC Grant 2Q07 Financial Report

	Z	AA	AB
1		TOTALS	
2	4th Qtr.		
3			
4		20,045,469	
5			
6		2,683,327	
7		2,637,449	
8		73,107	
9		45,878	
10			
11		2,208,326	
12		2,070,487	
13		73,101	
14		137,839	
15			
16		10,491,402	
17		10,585,942	
18		304,798	
19		(94,540)	
20			
21		63,619	
22		9,113	
23		4,061	
24		54,506	
25			
26		1,629,320	
27		1,383,490	
28		18,275	
29		245,830	
30			
31		1,256,775	
32		1,253,836	
33		34,520	
34		2,939	
35			
36		18,332,769	
37		17,940,317	
38		507,862	
39		392,452	
40			
41		18,332,769	
42		17,940,317	
43		392,452	
44			
45			
46			
47			
48			
49			
50			
51			

Benzene Health Research Consortium
UCHSC Subcontract 2Q07 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L
1	UCHSC	2001	2002		2003				2004			
2	Subcontracts	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.		3rd & 4th Qtr.		1st & 2nd Qtr.		3rd & 4th Qtr.		1st & 2nd Qtr.
3	Fudan University											
4	Actual expense	-	-	411,935		468,341		1,088,352		880,342		760,876
5	IPHSC											
6	Actual expense	-	-	8,339		27,496		7,683		-		-
7	SMCDCP											
8	Actual expense	-	-	45,563		24,766		2,500		-		-
9	EMBSI											
10	Actual expense	-	-	372,725		-		-		-		547,863
11	Children's Hospital Cincinnati											
12	Actual expense	-	-	7,298		45,267		29,972		68,354		50,575
13	TOTALS	2001	2002		2003			2004				
14	Actual expense	-	1,025,372	845,860		565,870		1,128,507		948,696		1,359,314
15								\$1,128,507				
16		DRAFT										
17		*Total subcontractor expenses* from study report (preliminary figure); *actual expenses* from UC Office of Grants & Contracts spreadsheet (final figures).										
18	LT 8/3/2005	** 2002 subcontractor costs not broken out by UCHSC, so this must be added back into the sum of row totals for total subcontractor costs to balance										
19	BJ 8/02/05											
20	RT 7/19/06											

Benzene Health Research Consortium
UCHSC Subcontract 2Q07 Financial Report

	M	N	O	P	Q	R	S	T	U	V	W
1	2005				2006				2007		TOTALS**
2	bdgtd '05	3rd & 4th Qtr.		1st & 2nd Qtr.	bdgtd '06	3rd & 4th Qtr.		1st & 2nd Qtr.	bdgtd '07	3rd & 4th Qtr.	
3											
4	1,676,855	540,271		971,463	1,651,285	754,319		-	159,600	-	9,363,639
5											
6	12,000	124,059		2,500	-	-		-	-	-	182,077
7											
8	-	80,175		-	3,000	-		-	3,000	-	159,004
9											
10	862,823	952,967		642,199	931,939	457,834		-	407,700	-	5,176,050
11											
12	112,000	75,892		59,476	117,600	51,168		-	39,295	-	656,897
13	2005				2006				2007		
14	2,863,678	1,773,364		1,675,638	2,703,824	1,263,321		-	609,595	-	16,563,039
15	1331839				1351912				304797.5		
16											
17											
18											
19											
20											

Benzene Health Research Consortium
Irons Field Expenses 2Q07 Financial Report

	A	B	C	D	E
1	IRONS T&E (X8106)	2001	2002		
2	Cost Centers	4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.
3	Payments				
4	Disbursed	145,763	393,723	-	-
5	Airfare & related expenses				
6	Budgeted	1,280	103,624	55,343	27,672
7	Actual expense	1,606	75,179	27,359	25,079
8	Current Variance	(326)	28,445	27,984	2,593
9	Cumm Variance	(326)	28,119	56,103	58,696
10	Apartment / hotel & related expenses				
11	Budgeted	1,280	103,624	55,343	27,672
12	Actual expense	1,024	89,717	45,291	21,200
13	Current Variance	256	13,907	10,052	6,472
14	Cumm Variance	256	14,163	24,216	30,687
15	Other expenses e.g. taxi, limo, misc.				
16	Budgeted	640	51,812	27,672	13,836
17	Actual expense	528	30,653	16,926	8,103
18	Current Variance	112	21,159	10,746	47,240
19	Cumm Variance	112	21,272	32,017	79,257
20	TOTALS	2001	2002		
21	Budgeted	3,200	259,080	138,359	69,179
22	Actual expense	3,157	195,549	89,577	54,382
23	Current Variance	43	63,511	48,782	14,797
24	Cumm Variance	43	63,554	112,336	127,133
25	CUMULATIVE TOTALS	2001	2002		
26	Budgeted	3,200	262,280	400,619	469,798
27	Expense	3,157	198,708	288,283	342,665
28	Variance	43	63,554	112,336	127,133
29					
30	Blue: future cumulative variance has no meaning until Expense entered.	"Actual expense" is from quarterly expense reports, and does not reflect contract prepayments			
31					
32		Amt paid to Irons to date:		\$919,486	numbers as of 6/30/05
33		Amt Irons has spent:		\$872,369	note - 1Q05 & 2Q05 expenses recprded in 2Q05
34	LT 8/24/05	Amt. In Irons bank acct:		\$47,117	
35	BJ 8/24/05				
36	RT 8/1/2007	RT: See comments in cells M22 and M23			
37	DRAFT				

Benzene Health Research Consortium
Irons Field Expenses 2Q07 Financial Report

	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V
1	2003	2004				2005				2006				2007			
2	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.
3																	
4	-	-	189,320	-	59,680	131,000	-	131,000	-	131,000	-	-	131,000	-	55,000		-
5																	
6	22,200	22,200	22,200	22,200	22,200	22,200	22,200	22,200	22,200	22,200	22,200	22,200	22,200	22,200	22,200	22,200	22,200
7	74,850	18,124	32,651	14,144	29,290	-	52,969	22,913	21,130	16,819	-	-	-	-	-	-	-
8	(52,650)	4,076	(10,451)	8,058	(7,090)	22,200	(30,769)	(713)	1,070	5,381	22,200	22,200	22,200	22,200	22,200	22,200	22,200
9	6,046	10,122	(329)	7,728	637	22,837	(7,932)	(8,645)	(7,575)	(2,194)	20,006	42,206	64,406	86,606	108,806	131,006	153,206
10																	
11	22,205	22,205	22,205	22,205	22,205	22,205	22,205	22,205	22,205	22,205	22,205	22,205	22,205	22,205	22,205	22,205	22,205
12	61,131	20,041	55,100	26,225	15,200	-	45,600	26,225	22,800	22,800	-	-	-	-	-	-	-
13	(58,926)	2,164	(32,895)	(4,020)	7,005	22,205	(23,395)	(4,020)	(595)	(595)	22,205	22,205	22,205	22,205	22,205	22,205	22,205
14	(28,239)	(26,075)	(58,970)	(62,990)	(55,985)	(33,780)	(57,175)	(61,195)	(61,790)	(62,385)	(40,180)	(17,975)	4,230	26,435	48,640	70,845	93,050
15																	
16	11,103	11,103	11,103	11,103	11,103	11,103	11,103	11,103	11,103	11,103	11,103	11,102	11,102	11,102	11,102	11,102	11,102
17	13,625	5,780	7,658	9,021	15,937	-	12,358	6,900	17,945	3,869	-	-	-	-	-	-	-
18	(2,522)	5,323	3,445	2,082	(4,834)	11,103	(1,255)	4,203	(6,842)	7,234	11,103	11,102	11,102	11,102	11,102	11,102	11,102
19	76,735	82,058	85,503	87,585	82,751	93,854	92,598	96,802	89,961	97,195	108,298	119,400	130,502	141,604	152,706	163,808	174,910
20	2003	2004				2005				2006				2007			
21	55,508	55,508	55,508	55,508	55,508	55,508	55,508	55,508	55,508	55,508	55,508	55,507	55,507	55,507	55,507	55,507	55,507
22	169,606	43,945	95,409	49,390	60,427	-	110,927	56,038	61,875	43,488	68,415	-	-	-	-	-	-
23	(114,098)	11,563	(39,901)	6,118	(4,919)	55,508	(55,419)	(530)	(6,367)	12,020	(12,907)	55,507	55,507	55,507	55,507	55,507	55,507
24	13,035	24,598	(15,303)	(9,185)	(14,104)	41,404	(14,015)	(14,545)	(20,912)	(8,891)	(21,798)	33,709	89,216	144,723	200,230	255,737	311,244
25	2003	2004				2005				2006				2007			
26	525,306	590,814	636,322	691,830	747,338	802,846	858,354	913,862	969,370	1,024,878	1,080,386	1,135,893	1,191,400	1,246,907	1,302,414	1,357,921	1,413,428
27	512,270	556,215	651,624	701,014	761,442	761,442	872,369	928,407	990,282	1,033,769	1,102,184	1,102,184	1,102,184	1,102,184	1,102,184	1,102,184	1,102,184
28	13,035	24,598	(15,303)	(9,185)	(14,104)	41,404	(14,015)	(14,545)	(20,912)	(8,891)	(21,798)	33,709	89,216	144,723	200,230	255,737	311,244
29	4Q03 ADJUSTMENT - 2001/2002 expense underrecorded; +\$114,289 adjustment																
30																	
31																	
32																	
33																	
34																	
35																	
36																	
37																	

Benzene Health Research Consortium
Irons Field Expenses 2Q07 Financial Report

	W
1	TOTALS
2	
3	
4	1,367,486
5	
6	565,319
7	412,113
8	64,406
9	153,206
10	
11	565,404
12	472,354
13	4,230
14	93,050
15	
16	282,705
17	149,902
18	130,502
19	133,403
20	
21	1,413,428
22	1,102,184
23	89,216
24	311,244
25	
26	1,413,428
27	1,102,184
28	311,244
29	
30	
31	
32	
33	
34	
35	
36	
37	

**Benzene Health Research Consortium
AHS 2Q07 Financial Report**

	A	B	C	D	E	F	G	H	I	J	K
1	AHS (X8107)	2001	2002			2003			2004		
2	Cost Centers	4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.
3	Labor										
4	Budgeted	84,025	290,013	157,756	78,878	78,878	72,090	72,090	72,090	72,090	84,217
5	Actual expense	134,134	394,505	124,124	137,280	73,690	-	149,980	92,201	162,216	70,316
6	Current Variance	(50,109)	(104,492)	33,632	(58,402)	5,188	72,090	(77,890)	(20,111)	(90,126)	13,901
7	Cumm Variance	(50,109)	(154,601)	(120,970)	(179,372)	(174,184)	(102,094)	(179,984)	(200,094)	(290,220)	(276,319)
8	Travel & expenses										
9	Budgeted	-	140,000	57,000	28,500	28,500	25,500	25,500	25,500	25,500	25,500
10	Actual expense	2,118	39,458	16,541	12,109	16,413	-	18,534	12,522	2,564	-
11	Current Variance	(2,118)	100,542	40,459	16,391	12,087	25,500	6,966	12,978	22,936	25,500
12	Cumm Variance	(2,118)	98,424	138,893	155,274	167,361	192,861	199,827	212,805	235,741	261,241
13	Other direct expenses										
14	Budgeted	-	5,500	1,500	750	750	750	750	750	750	750
15	Actual expense	77	1,443	-	-	-	-	109	785	211	-
16	Current Variance	(77)	4,057	1,500	750	750	750	641	(35)	539	750
17	Cumm Variance	(77)	3,980	5,480	6,230	6,980	7,730	8,371	8,336	8,875	9,625
18	TOTALS	2001	2002			2003			2004		
19	Budgeted	84,025	435,513	216,256	108,128	108,128	98,340	98,340	98,340	98,340	110,467
20	Actual expense	136,329	435,406	140,665	149,389	90,103	-	168,623	105,508	164,991	70,316
21	Current Variance	(52,304)	107	75,591	(41,261)	18,025	98,340	(70,283)	(7,168)	(66,651)	40,151
22	Cumm Variance	(52,304)	(52,197)	23,394	(17,868)	157	98,497	28,215	21,047	(45,604)	(5,454)
23	CUMULATIVE TOTALS	2001	2002			2003			2004		
24	Budgeted	84,025	519,538	735,794	843,921	952,049	1,050,389	1,148,730	1,247,070	1,345,410	1,455,877
25	Expense	136,329	571,735	712,400	861,789	951,892	951,892	1,120,515	1,226,023	1,391,014	1,481,330
26	Variance	(52,304)	(52,197)	23,394	(17,868)	157	98,497	28,215	21,047	(45,604)	(5,454)
27	Blue: future cumulative variance has no meaning until Expense entered.					4Q03 Adjustment: expense reduced by \$52,634; transferred to contingency since these were pre-consortia expenses					
28											
29											
30	LT 8/3/05	DRAFT									
31	BJ 4/05/05										
32	RT 8/1/2007										

Benzene Health Research Consortium
AHS 2Q07 Financial Report

	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA
1	2005			2006				2007				2008				TOTALS
2	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3																
4	158,934	98,617	98,617	91,867	91,867	91,867	91,867	160,292	160,292	160,292	160,292	175,876	175,876	175,876	175,876	3,130,435
5	120,880	115,825	222,365	73,855	111,422	141,140	231,797	112,560	173,692	-	-					2,641,982
6	38,054	(17,208)	(123,748)	18,012	(19,555)	(49,273)	(139,930)	47,732	(13,400)	160,292	160,292					160,292
7	38,054	20,846	(102,903)	(84,890)	(104,445)	(153,718)	(293,648)	(245,916)	(259,316)	(99,024)	61,268					488,453
8																
9	43,350	34,425	34,425	44,371	44,371	44,371	44,371									671,184
10	1,899	16,622	-	-	-	-	-		-	-	-					138,780
11	41,451	17,803	34,425	44,371	44,371	44,371	44,371	-	-	-	-					-
12	41,451	59,254	93,679	138,050	182,421	226,792	271,163	271,163	271,163	271,163	271,163					532,404
13																
14	750	750	750	750	750	750	750		-	-	-					17,500
15	335	478	-	-	-	-	-	-	-	-	-					3,438
16	415	272	750	750	750	750	750	-	-	-	-					-
17	415	687	1,437	2,187	2,937	3,687	4,437	4,437	4,437	4,437	4,437					14,062
18	2005			2006				2007				2008				
19	203,034	133,792	133,792	136,988	136,988	136,988	136,988	160,292	160,292	160,292	160,292	175,876	175,876	175,876	175,876	3,819,119
20	123,114	132,925	222,365	73,855	111,422	141,140	231,797	112,560	173,692	-	-					2,784,201
21	79,920	867	(88,573)	63,133	25,566	(4,152)	(94,809)	47,732	(13,400)	160,292	160,292					160,292
22	79,920	80,787	(7,787)	55,347	80,913	76,761	(18,048)	29,684	16,284	176,576	336,868					1,034,919
23	2005			2006				2007				2008				
24	1,664,364	1,798,156	1,931,948	2,068,936	2,205,924	2,342,913	2,479,901	2,640,193	2,800,485	2,960,777	3,121,069					3,121,069
25	1,584,444	1,717,369	1,939,734	2,013,589	2,125,011	2,266,152	2,497,948	2,610,508	2,784,201	2,784,201	2,784,201					2,784,201
26	79,920	80,787	(7,787)	55,347	80,913	76,761	(18,048)	29,684	16,284	176,576	336,868					336,868
27																
28																
29																
30																
31																
32	581,084				547,953				641,168							

**Benzene Health Research Consortium
Fudan 2Q07 Financial Report**

	A	B	C	D	E	F	G	H	I	J	K	L		M	N
1	FUDAN (X8108)	2001	2002	2003		2004				2005					
2	Cost Centers			1Q/2Q03	3Q03	4Q03	1Q04	2Q04	3Q04	4Q04	1Q05	2Q05		3Q05	4Q05
3	Labor (salary + benefits)														
4	Budgeted	9,620	8,775	4,388	2,194	1,548	1,548	1,548	1,548	1,548	-	4,777		-	4,778
5	Actual expense	-	8,774	6,492	-	-	-	14,385	-	46,409	-	-		-	-
6	Current Variance	9,620	1	(2,105)	2,194	1,548	1,548	(12,837)	1,548	(44,861)	-	4,777		-	4,778
7	Cumm Variance	9,620	9,621	7,516	9,709	11,257	12,805	(32)	1,516	(43,345)	(43,345)	4,777		4,777	9,555
8	Expenses														
9	Budgeted	17,600	28,400	14,200	7,100	4,645	4,645	4,645	4,645	4,645	-	30,250		-	30,250
10	Actual expense	-	4,870	-	8,851	1,168	-	9,750	-	10,983	-	-		-	4,007
11	Current Variance	17,600	23,530	14,200	(1,751)	3,477	4,645	(5,105)	4,645	(6,338)	-	30,250		-	26,243
12	Cumm Variance	17,600	41,130	55,330	53,579	57,056	61,701	56,596	61,241	54,903	54,903	30,250		30,250	56,493
13	Overhead (15%)														
14	Budgeted	4,083	5,576	2,788	1,394	1,095	1,095	1,095	1,095	1,094	-	5,254		-	5,254
15	Actual expense	-	1,825	-	-	-	-	3,620	-	6,961	-	-		-	-
16	Current Variance	4,083	3,751	2,788	1,394	1,095	1,095	(2,525)	1,095	(5,867)	-	5,254		-	5,254
17	Cumm Variance	4,083	7,834	10,622	12,016	13,111	14,206	11,681	12,776	6,909	6,909	5,254		5,254	10,508
18	TOTALS	2001	2002	2003			2004				2005				
19	Budgeted	31,303	42,751	21,376	10,688	7,288	7,288	7,288	7,288	7,287	-	40,281		-	40,282
20	Actual expense	-	15,470	6,492	8,851	1,168	-	27,755	-	64,354	-	-		-	4,007
21	Current Variance	31,303	27,281	14,883	1,837	6,120	7,288	(20,467)	7,288	(57,067)	-	40,281		-	36,275
22	Cumm Variance	31,303	58,584	73,467	75,305	81,425	88,713	68,246	75,534	18,467	18,467	40,281		40,281	76,556
23	CUMULATIVE TOTALS	2001	2002	2003			2004				2005				
24	Budgeted	31,303	74,054	95,430	106,117	113,405	120,693	127,981	135,269	142,556	142,556	164,371		164,371	204,653
25	Expense	-	15,470	21,962	30,813	31,981	31,981	59,736	59,736	124,090	124,090	124,090		124,090	128,097
26	Variance	31,303	58,584	73,467	75,305	81,425	88,713	68,246	75,534	18,467	18,467	40,282		40,282	76,557
27	Blue: future cumulative variance has no meaning until Expense entered.														
28															
29	LET 8/3/05	DRAFT													
30	BJ 8/01/05														
31	rdw 10/19/06														
32	RT 10/26/06														
												2005 - variance zeroed out - only current cgr variance shown			
												2005 - expense projections revised based on 3 May 05 approved budget			

Benzene Health Research Consortium
Fudan 2Q07 Financial Report

	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA
1		2006				2007				2008			TOTALS
2	1Q06	2Q06	3Q06	4Q06	1Q07	2Q07	3Q07	4Q07	1Q07	2Q07	3Q07	4Q07	
3													
4	-	5,614	-	5,614	-	6,507	-	6,507					109,856
5	-	-	9,555	-	-	-	-	-					85,616
6	-	5,614	(9,555)	5,614	-	6,507	-	6,507					6,507
7	9,555	15,169	5,614	11,227	11,227	17,734	17,734	24,240					24,240
8													
9	-	33,750		33,750	-	25,775	-	25,775					215,172
10	-	-	56,860	-	-	-	-	-					96,489
11	-	33,750	(56,860)	33,750	-	25,775	-	25,775					25,775
12	56,493	90,243	33,383	67,133	67,133	92,908	92,908	118,683					118,683
13													
14	-	7,873		7,873	-	8,071		8,071					54,800
15	-	-	9,962	-	-	-	-	-					22,369
16	-	7,873	(9,962)	7,873	-	8,071	-	8,071					8,071
17	10,508	18,380	8,418	16,290	16,290	24,361	24,361	32,431					32,432
18		2006				2007							
19	-	47,236	-	47,236	-	50,000	-	50,000	10,000	10,000	10,000	10,000	439,125
20	-	-	76,377	-	-	-	-	-					204,474
21	-	47,236	(76,377)	47,236	-	50,000	-	50,000					50,000
22	76,556	123,792	47,415	94,651	94,651	144,651	144,651	194,651					234,651
23		2006				2007							
24	204,853	251,889	251,889	299,125	299,125	349,125	349,125	399,125					399,125
25	128,097	128,097	204,474	204,474	204,474	204,474	204,474	204,474					204,474
26	76,557	123,793	47,415	94,651	94,651	144,651	144,651	194,651					194,651
27	Note: budget is in 2001 \$.												
28													
29													
30													
31													
32													

Benzene Health Research Consortium
SRP + ERP 2007 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V
	SRP + ERP (X8109)	2001	2002	2003			2004				2005				2006				2007			
	Cost Centers	4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.
Albertini																						
	Budgeted	2,160	8,640	4,320	2,160	322	(13,073)	-	250	3,000	-	-	250	3,000	-	-	3,750	-	-	-	3,750	-
	Actual expense	2,000	-	-	-	2,529	-	-	3,401	-	-	-	-	-	1,000	-	2,443	-	-	-	-	-
	Current Variance	160	8,640	4,320	2,160	(2,207)	(13,073)	-	250	(401)	-	-	250	3,000	(1,000)	-	1,307	-	-	-	3,750	-
	Cumm Variance	160	8,800	13,120	15,280	13,073	-	-	250	(151)	(151)	(151)	99	3,099	2,099	2,099	3,406	3,406	3,406	3,406	7,156	7,156
Brody (DB5200X1503; resigned 4Q03)																						
	Budgeted	2,160	8,640	4,320	2,160	322	(17,602)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Actual expense	-	-	-	-	-	-	1,500	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Current Variance	2,160	8,640	4,320	2,160	322	(17,602)	(1,500)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Cumm Variance	2,160	10,800	15,120	17,280	17,602	-	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)
Checkoway																						
	Budgeted	2,160	8,640	4,320	2,160	322	(14,180)	-	250	3,000	-	-	250	3,000	-	-	3,750	-	-	-	3,750	-
	Actual expense	1,000	-	-	2,422	-	-	-	3,036	-	-	-	-	4,609	-	-	-	-	-	-	-	-
	Current Variance	1,160	8,640	4,320	(262)	322	(14,180)	-	250	(36)	-	-	250	(1,609)	-	-	3,750	-	-	-	3,750	-
	Cumm Variance	1,160	9,800	14,120	13,858	14,180	-	-	250	214	214	214	464	(1,145)	(1,145)	(1,145)	2,605	2,605	2,605	2,605	6,355	6,355
Cherrie / IOM																						
	Budgeted	2,160	8,640	4,320	2,160	322	(15,480)	-	250	8,000	-	-	250	8,000	-	-	6,500	-	-	-	6,500	-
	Actual expense	-	2,122	-	-	-	-	7,029	-	10,229	-	-	-	8,090	-	-	-	10,907	-	-	-	-
	Current Variance	2,160	6,518	4,320	2,160	322	(15,480)	(7,029)	250	(2,229)	-	-	250	(90)	-	-	6,500	(10,907)	-	-	6,500	-
	Cumm Variance	2,160	8,678	12,998	15,158	15,480	(0)	(7,029)	(6,779)	(9,008)	(9,008)	(9,008)	(8,758)	(8,848)	(8,848)	(8,848)	(2,348)	(13,255)	(13,255)	(13,255)	(6,755)	(6,755)
Greim																						
	Budgeted	2,160	8,640	4,320	2,160	322	(10,268)	-	250	8,000	-	-	250	8,000	-	-	8,482	-	-	-	8,482	-
	Actual expense	-	-	-	-	7,334	-	-	3,338	-	-	-	-	7,698	-	-	7,894	-	-	-	-	-
	Current Variance	2,160	8,640	4,320	2,160	(7,012)	(10,268)	-	250	4,662	-	-	250	302	-	-	588	-	-	-	8,482	-
	Cumm Variance	2,160	10,800	15,120	17,280	10,268	-	-	250	4,912	4,912	4,912	5,162	5,464	5,464	5,464	6,052	6,052	6,052	6,052	14,534	14,534
Herrick																						
	Budgeted	2,160	8,640	4,320	2,160	322	(11,148)	-	250	3,000	-	-	250	3,000	-	-	3,900	-	-	-	3,900	-
	Actual expense	2,000	-	-	-	4,454	-	-	415	-	-	-	-	-	-	-	4,941	-	-	-	-	-
	Current Variance	160	8,640	4,320	2,160	(4,132)	(11,148)	-	250	2,585	-	-	250	3,000	-	-	3,900	(4,941)	-	-	3,900	-
	Cumm Variance	160	8,800	13,120	15,280	11,148	-	-	250	2,835	2,835	2,835	3,085	6,085	6,085	6,085	9,985	5,044	5,044	5,044	8,944	8,944
Idanpaan-Heikkila																						
	Budgeted	2,160	8,640	4,320	2,160	322	(13,078)	-	250	8,000	-	-	250	8,000	-	-	10,000	-	-	-	10,000	-
	Actual expense	-	-	4,344	180	-	-	-	7,620	-	-	-	-	11,359	-	-	10,586	-	-	-	-	-
	Current Variance	2,160	8,640	(24)	1,980	322	(13,078)	-	250	380	-	-	250	(3,359)	-	-	(586)	-	-	-	10,000	-
	Cumm Variance	2,160	10,800	10,776	12,756	13,078	0	0	250	630	630	630	880	(2,479)	(2,479)	(2,479)	(3,065)	(3,065)	(3,065)	(3,065)	6,935	6,935
Larson																						
	Budgeted	2,160	8,640	4,320	2,160	322	(12,839)	-	250	3,000	-	-	250	3,000	-	-	4,000	-	-	-	4,000	-
	Actual expense	2,127	-	-	2,636	-	-	-	2,850	-	-	-	-	3,939	-	-	2,729	-	-	-	-	-
	Current Variance	33	8,640	4,320	(476)	322	(12,839)	-	250	150	-	-	250	(939)	-	-	1,271	-	-	-	4,000	-
	Cumm Variance	33	8,673	12,993	12,517	12,839	-	-	250	400	400	400	650	(289)	(289)	(289)	982	982	982	982	4,982	4,982
Li																						
	Budgeted	2,160	8,640	4,320	2,160	322	5,288	-	250	10,000	-	-	250	10,000	-	-	10,000	-	-	-	10,000	-
	Actual expense	6,796	3,000	-	-	13,094	-	-	6,477	-	-	-	-	-	-	-	9,300	-	-	-	-	-
	Current Variance	(4,636)	5,640	4,320	2,160	(12,772)	5,288	-	250	3,523	-	-	250	10,000	-	-	700	-	-	-	10,000	-
	Cumm Variance	(4,636)	1,004	5,324	7,484	(5,288)	0	0	250	3,773	3,773	3,773	4,023	14,023	14,023	14,023	14,723	14,723	14,723	14,723	24,723	24,723
Minden / Ontario Cancer Institute (discontinued 2006)																						
	Budgeted	2,160	8,640	4,320	2,160	322	(16,602)	-	250	3,000	-	-	250	3,000	-	-	-	-	-	-	-	-
	Actual expense	1,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Current Variance	1,160	8,640	4,320	2,160	322	(16,602)	-	250	3,000	-	-	250	3,000	-	-	-	-	-	-	-	-
	Cumm Variance	1,160	9,800	14,120	16,280	16,602	-	-	250	3,250	3,250	3,250	3,500	6,500	6,500	6,500	6,500	6,500	6,500	6,500	6,500	6,500
Mueller (resigned 2Q03)																						
	Budgeted	2,160	8,640	4,320	2,160	322	(16,352)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Actual expense	1,250	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Current Variance	910	8,640	4,320	2,160	322	(16,352)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Cumm Variance	910	9,550	13,870	16,030	16,352	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rice																						
	Budgeted	2,160	8,640	4,320	2,160	322	(5,410)	3,000	1,500	4,000	1,500	1,000	1,000	2,000	1,000	1,000	4,500	4,500	4,500	4,500	4,500	4,500
	Actual expense	-	-	4,000	5,692	2,000	500	3,500	2,500	6,311	-	2,500	14,016									

	W
1	TOTALS
2	
3	
4	20,176
5	11,373
6	-
7	8,802
8	
9	1,500
10	1,500
11	-
12	-
13	
14	19,371
15	11,067
16	-
17	8,304
18	
19	41,137
20	38,377
21	-
22	2,760
23	
24	35,834
25	26,264
26	-
27	9,570
28	
29	18,870
30	11,810
31	-
32	7,060
33	
34	44,170
35	34,089
36	-
37	10,081
38	
39	20,053
40	14,281
41	-
42	5,772
43	
44	62,722
45	38,667
46	-
47	14,055
48	
49	1,000
50	1,000
51	-
52	-
53	
54	1,250
55	1,250
56	-
57	-
58	
59	88,338
60	90,493
61	4,500
62	(2,155)
63	
64	20,710
65	8,210
66	-
67	12,500
68	
69	65,513
70	34,679
71	-
72	30,834
73	
74	22,500
75	11,872
76	-
77	10,628
78	
79	20,000
80	15,284
81	-
82	4,716
83	
84	473,143
85	365,158
86	4,500
87	63,971
88	
89	429,129
90	365,158
91	63,971
92	

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V
	Blue: future cumulative variance has no meaning until Expense entered.																					
							1Q04 budget adjustments to zero our variance to develop more useful budget projections for remainder of program. Change approved by OC at 4/21/04 meeting.															
93																						
94																						
95	LT 8/3/05	DRAFT																				
96	BJ 4/05/05																					
97	rdw 10/19/06																					
98	RT 8/1/2007																					

**Benzene Health Research Consortium
Communications 2Q07 Financial Report**

	A	B	C	D	E	F	G	H	I	J	K	L
1	COMMUNICATIONS (X8103)	2001	2002	2003	2004							20
2	Cost Centers	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr. ²	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr. ²	1st Qtr.	2nd Qtr.
3	APCO											
4	Budgeted	57,600	230,400	120,000	60,000	(187,396)	14,401	14,400	14,400	(39,906)		
5	Actual expense	-	232,229	14,483	7,351	26,541	-	790	1,235	1,270	-	-
6	CurrentVariance	57,600	(1,829)	105,517	52,649	(213,937)	14,401	13,610	13,165	(41,176)	-	-
7	Cumm Variance	57,600	55,771	161,288	213,937	(0)	14,401	28,011	41,176	(0)	(0)	(0)
8	Travel											
9	Budgeted	1,800	7,200	3,750	1,875	(5,876)	450	450	450	(1,350)		
10	Actual expense	-	7,091	-	526	1,132	-	-	-	-	-	-
11	CurrentVariance	1,800	109	3,750	1,349	(7,008)	450	450	450	(1,350)	-	-
12	Cumm Variance	1,800	1,909	5,659	7,008	0	450	900	1,350	0	0	0
13	Other1											
14	Budgeted	600	2,400	1,250	625	(3,364)	150	150	150	(448)		
15	Actual expense	-	1,417	80	-	15	-	-	-	-	-	-
16	CurrentVariance	600	983	1,170	625	(3,379)	150	150	150	(448)	-	-
17	Cumm Variance	600	1,583	2,753	3,378	(2)	148	298	448	0	0	0
18												
19	Budgeted	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
20	Actual expense	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
21	CurrentVariance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
22	Cumm Variance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
23												
24	Budgeted	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
25	Actual expense	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
26	CurrentVariance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
27	Cumm Variance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
28												
29	Budgeted	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
30	Actual expense	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
31	CurrentVariance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
32	Cumm Variance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
33												
34	Budgeted	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
35	Actual expense	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
36	CurrentVariance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
37	Cumm Variance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
38	TOTALS	2001	2002	2003	2004							20
39	Budgeted	60,000	240,000	125,000	62,500	(196,636)	15,001	15,000	15,000	(41,704)	-	-
40	Actual expense	-	240,738	14,564	7,877	27,688	-	790	1,235	1,270	-	-
41	CurrentVariance	60,000	(738)	110,436	54,623	(224,324)	15,001	14,210	13,765	(42,974)	-	-
42	Cumm Variance	60,000	59,262	169,699	224,322	(2)	14,999	29,209	42,974	0	0	0
43	CUMULATIVE TOTALS	2001	2002	2003	2004							20
44	Budgeted	60,000	300,000	425,000	487,500	290,864	305,865	320,865	335,865	294,161	294,161	294,161
45	Expense	-	240,738	255,301	263,178	290,866	290,866	291,656	292,891	294,161	294,161	294,161
46	Variance	60,000	59,262	169,699	224,322	(2)	14,999	29,209	42,974	0	0	0
47	- Telecommunications, Consulting Services, Duplicating/Copies Internal, Postage, Couriers, Telephone, Meals, Lexis Nexis Searches											
48	Blue: future cumulative variance has no meaning until Expense entered.											
49	² - Budget adjustment reflects budget reduction from \$1MM to \$550k											
50												
51	LT 8/3/05											
52	RT 1/21/05											
53												
54	DRAFT	*budget adjustment to lower program budget from \$550K to \$300K, as approved by OC on 12/16/04										

**Benzene Health Research Consortium
Communications 2Q07 Financial Report**

	M	N	O	P	Q	R	S	T	U	V	W
1	2006										TOTALS
2	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3											
4											283,899
5	-	-	-	-	-	-	-	-	-	-	283,899
6	-	-	-	-	-	-	-	-	-	-	(0)
7	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
8											
9											8,749
10	-	-	-	-	-	-	-	-	-	-	8,749
11	-	-	-	-	-	-	-	-	-	-	0
12	0	0	0	0	0	0	0	0	0	0	0
13											
14		1,946				1,946				1,946	7,352
15	-	-	-	-	-	-	-	-	-	-	1,513
16	-	1,946	-	-	-	1,946	-	-	-	1,946	5,839
17	0	1,947	1,947	1,947	1,947	3,893	3,893	3,893	3,893	5,839	5,839
18											
19	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
20	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
21	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
22	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
23											
24	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
25	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
26	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
27	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
28											
29	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
30	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
31	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
32	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
33											
34	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
35	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
36	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
37	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
38	2006										
39	-	1,946	-	-	-	1,946	-	-	-	1,946	300,000
40	-	-	-	-	-	-	-	-	-	-	294,161
41	-	1,946	-	-	-	1,946	-	-	-	1,946	3,893
42	0	1,946	1,946	1,946	1,946	3,893	3,893	3,893	3,893	5,839	5,839
43	2006										
44	294,161	296,107	296,107	296,107	296,107	298,054	298,054	298,054	298,054	300,000	300,000
45	294,161	294,161	294,161	294,161	294,161	294,161	294,161	294,161	294,161	294,161	294,161
46	0	1,946	1,946	1,946	1,946	3,893	3,893	3,893	3,893	5,839	5,839
47											
48											
49											
50											
51											
52											
53											
54											

Benzene Health Research Consortium
Legal 2Q07 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P
1	LEGAL (X8104)	2001	2002	2003		2004				2005						
2	Cost Centers	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.*	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.
3	Step toe & Johnson															
4	Budgeted	30,000	120,000	62,500	31,250	(210,542)	4,175	4,175	4,175	4,175	4,175	7,811	7,811	7,811	7,811	7,811
5	Actual expense	-	13,565	1,728	-	17,915	365	2,995	1,870	26,092	4,827	16,769	-	12,110	5,776	6,084
6	Current Variance	30,000	106,435	60,772	31,250	(228,457)	3,810	1,180	2,305	(21,918)	(653)	(8,958)	7,811	(4,299)	2,035	1,727
7	Cumm Variance	30,000	136,435	197,207	228,457	0	3,810	4,990	7,294	(14,623)	(15,276)	(8,958)	(1,147)	(5,446)	(3,411)	(1,884)
8	CUMULATIVE TOTALS	2001	2002	2003		2004				2005						
9	Budgeted	30,000	150,000	212,500	243,750	33,208	37,383	41,557	45,732	49,906	54,081	77,167	84,978	92,789	100,600	108,411
10	Expense	-	13,565	15,293	15,293	33,208	33,572	36,567	38,437	64,529	69,356	86,125	86,125	98,235	104,011	110,096
11	Variance	30,000	136,435	197,207	228,457	0	3,810	4,990	7,294	(14,623)	(15,276)	(8,958)	(1,147)	(5,446)	(3,411)	(1,884)
12	Blue: future cumulative variance has no meaning until Expense entered.											2Q05 - variance adjusted to reflect only 2Q05 variance				
13												2Q05 - Budget revised from \$100K to \$140K per revised program budget approved 3 May 05				
14	* budget adjustment to lower program budget from \$500K to \$100K, as approved by OC on 11/11/03				\$54,081		\$85,920									
15							\$7,810.86									
16	LT 8/3/05	DRAFT														
17	RT 8/1/2007															
18																
19																
20																
21																
22		\$0	\$13,565	\$1,728	\$0	\$17,915	\$365	\$2,995	\$1,870	\$26,092	\$4,827	\$16,769	\$0	\$12,110	\$98,235	

Benzene Health Research Consortium
Legal 2Q07 Financial Report

	Q	R	S	T	U	V	W
1	2006						TOTALS
2	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3							
4	7,811	7,811	17,811	17,811	17,810	17,810	180,000
5	1,848	25,448	13,891	24,224	-	-	175,505
6	5,965	(17,637)	3,920	(6,413)	17,810	17,810	4,495
7	4,281	(13,356)	(9,436)	(15,849)	1,961	19,771	4,495
8	2007						
9	116,222	124,033	141,844	159,655	177,465	195,275	180,000
10	111,941	137,390	151,280	175,505	175,505	175,505	175,505
11	4,281	(13,356)	(9,436)	(15,849)	1,961	19,771	4,495
12							
13							
14							
15							
16							
17							
18							
19							
20							
21							
22							

**Benzene Health Research Consortium
QA-QC 2Q07 Financial Report**

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W
1	QA-QC	2001	2002	2003	2004	2005	2006	2007	TOTALS														
2	Cost Centers	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr**	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3	Contractor																						
4	Budgeted	13,500	54,000	28,126	14,063	(109,689)	6,250	6,250	6,250	(18,750)	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	50,000
5	Actual expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56	5,190	-	-	5,246
6	CurrentVariance	13,500	54,000	28,126	14,063	(109,689)	6,250	6,250	6,250	(18,750)	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,111	(1,023)	4,167	4,167	44,754
7	Cumm Variance	13,500	67,500	95,626	109,689	-	6,250	12,500	18,750	-	4,167	8,333	12,500	16,667	20,833	25,000	29,167	33,333	37,444	36,421	40,588	44,754	44,754
8	Travel																						
9	Budgeted	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	Actual expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,202	-	-	-	1,202
11	CurrentVariance	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1,202)	-	-	-	(1,202)
12	Cumm Variance	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1,202)	(1,202)	(1,202)	(1,202)	(1,202)
13	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
14	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
15	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
16	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
17																							
18	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
19	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
20	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
21	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
22																							
23	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
24	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
25	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
26	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
27																							
28	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
29	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
30	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
31	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
32																							
33	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
34	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
35	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
36	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
37	TOTALS	2001	2002	2003	2004	2005	2006	2007															
38	Budgeted	13,500	54,000	28,126	14,063	(109,689)	6,250	6,250	6,250	(18,750)	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	50,000
39	Actual expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56	5,190	-	-	6,448
40	CurrentVariance	13,500	54,000	28,126	14,063	(109,689)	6,250	6,250	6,250	(18,750)	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,167	4,111	(1,023)	4,167	4,167	43,552
41	Cumm Variance	13,500	67,500	95,626	109,689	-	6,250	12,500	18,750	-	4,167	8,333	12,500	16,667	20,833	25,000	29,167	32,131	36,242	35,219	39,385	43,552	43,552
42	CUMULATIVE TOTALS	2001	2002	2003	2004	2005	2006	2007															
43	Budgeted	13,500	67,500	95,626	109,689	-	6,250	12,500	18,750	-	4,167	8,333	12,500	16,667	20,833	25,000	29,167	33,333	37,500	41,667	45,833	50,000	50,000
44	Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,258	6,448	6,448	6,448	6,448
45	Variance	13,500	67,500	95,626	109,689	-	6,250	12,500	18,750	-	4,167	8,333	12,500	16,667	20,833	25,000	29,167	32,131	36,242	35,219	39,385	43,552	43,552
46	Blue: future cumulative variance has no meaning until Expense entered.																						
47																							
48	* budget adjustment to lower program budget from \$225K to \$100K, as approved by OC on 11/11/03	** budget adjustment to lower program budget from \$100K to \$50K, as approved by OC on 12/16/04																					
49																							
50	LT 8/3/05	DRAFT																					
51	RT 2/15/07																						

Benzene Health Research Consortium
API Administration 2Q07 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N
1	API	2000	2001	2002	2003		2004				2005			
2	Cost Centers	1st - 4th Qtr.	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.
3	Salaries													
4	Budgeted	-	26,045	104,180	54,260	27,130	22,250	22,000	22,000	22,000	20,000	12,000	20,000	15,000
5	Actual expense	9,039	18,749	89,669	57,297	32,217	32,800	26,745	25,357	21,839	21,813	16,492	19,319	19,814
6	CurrentVariance	(9,039)	6,552	14,511	(3,037)	(5,087)	(10,550)	(4,745)	(3,357)	161	(1,813)	(4,492)	681	(4,814)
7	Cumm Variance	(9,039)	(2,487)	12,024	8,987	3,900	(6,650)	(11,395)	(14,752)	(14,591)	(16,404)	(20,896)	681	(4,133)
8	Employee Benefits													
9	Budgeted	-	3,256	13,022	6,783	3,391	2,750	3,000	3,000	3,000	2,900	1,100	2,400	1,800
10	Actual expense	774	2,329	11,209	7,163	4,027	4,100	3,343	3,169	2,730	2,727	2,061	2,414	2,476
11	CurrentVariance	(774)	927	1,813	(380)	(636)	(1,350)	(343)	(169)	270	173	(961)	(14)	(676)
12	Cumm Variance	(774)	153	1,966	1,586	950	(400)	(743)	(912)	(642)	(469)	(1,430)	(14)	(690)
13	Employee Business Expenses / Travel													
14	Budgeted	-	3,256	13,022	6,783	3,391	7,500	1,000	1,000	3,000	1,000	1,000	1,000	1,000
15	Actual expense	342	1,487	8,004	308	1,683	7,313	-	1,152	2,027	1,710	716	542	94
16	CurrentVariance	(342)	1,769	5,018	6,475	1,708	187	1,000	(152)	973	(710)	284	458	906
17	Cumm Variance	(342)	1,427	6,445	12,920	14,628	14,815	15,815	15,663	16,636	15,926	16,210	458	1,364
18	Other Operating Expenses (& mtgs)													
19	Budgeted	-	651	2,604	1,359	679	16,184	2,000	2,000	6,000	2,000	430	1,000	1,000
20	Actual expense	1,673	9,196	16,270	13,292	72	26,276	3,600	3,808	(3,223)	11,398	2,010	684	1,209
21	CurrentVariance	(1,673)	(8,545)	(13,666)	(11,933)	607	(10,092)	(1,600)	(1,808)	9,223	(9,398)	(1,580)	316	(209)
22	Cumm Variance	(1,673)	(10,218)	(23,884)	(35,817)	(35,210)	(45,302)	(46,902)	(48,710)	(39,487)	(48,885)	(50,465)	316	107
23	API Recovered Overhead													
24	Budgeted	-	8,465	33,858	17,635	8,817	6,250	6,200	6,200	6,200	6,000	3,500	5,600	4,200
25	Actual expense	5,752	4,687	25,110	16,043	9,021	9,185	7,489	7,099	6,115	6,107	4,618	5,410	5,547
26	CurrentVariance	(5,752)	3,778	8,748	1,592	(204)	(2,935)	(1,289)	(899)	85	(107)	(1,118)	190	(1,347)
27	Cumm Variance	(5,752)	(1,974)	6,774	8,366	8,162	5,227	3,938	3,039	3,124	3,017	1,899	190	(1,157)
28	API Allocated Costs													
29	Budgeted	-	16,929	67,717	35,269	17,635	15,250	28,000	28,000	28,000	28,000	10,000	14,000	12,000
30	Actual expense	-	13,886	58,794	34,213	19,478	17,231	28,000	27,999	28,000	27,999	6,999	6,999	6,999
31	CurrentVariance	-	3,043	8,923	1,056	(1,843)	(1,981)	-	1	-	1	3,001	7,001	5,001
32	Cumm Variance	-	3,043	11,966	13,022	11,179	9,198	9,198	9,199	9,199	9,200	12,201	7,001	12,002
33	Supported Expense													
34	Budgeted	-	6,511	26,045	13,565	6,783	5,750	4,500	4,500	4,500	4,500	1,250	4,500	4,500
35	Actual expense	7,020	1,712	-	17,000	8,499	(8,250)	(4,023)	4,500	4,500	4,500	4,500	4,500	4,500
36	CurrentVariance	(7,020)	4,799	26,045	(3,435)	(1,716)	14,000	8,523	-	-	-	(3,250)	-	-
37	Cumm Variance	(7,020)	(2,221)	23,824	20,389	18,673	32,673	41,196	41,196	41,196	41,196	37,946	-	-
38	TOTALS	2000	2001	2002	2003			2004					2005	
39	Budgeted	-	65,113	260,448	135,654	67,826	75,934	66,700	66,700	72,700	64,400	29,280	48,500	39,500
40	Actual expense	24,600	52,046	209,056	145,316	74,997	88,655	65,154	73,084	61,988	61,312	37,396	39,868	40,639
41	CurrentVariance	(24,600)	13,067	51,392	(9,662)	(7,171)	(12,721)	1,546	(6,384)	10,712	(11,854)	(8,116)	8,632	(1,139)
42	Cumm Variance	(24,600)	(11,533)	39,859	30,197	23,026	10,305	11,851	5,467	16,179	4,325	(3,791)	8,632	7,493
43	CUMULATIVE TOTALS	2000	2001	2002	2003			2004					2005	
44	Budgeted	-	65,113	325,561	461,215	529,041	604,975	671,675	738,375	811,075	875,475	904,755	953,255	992,755
45	Expense	24,600	76,646	285,702	431,018	506,015	594,670	659,824	732,908	794,896	871,150	908,546	948,414	989,053
46	Variance	(24,600)	(11,533)	39,859	30,197	23,026	10,305	11,851	5,467	16,179	4,325	(3,791)	8,632	3,702
47														
48	LT 8/1/05	DRAFT											2Q05 - variance reflects 2Q05 variance, only	
49	RT 8/1/2007												2Q05 - budgeted expenses revised to reflect 3 May 05 revised total program budget	
50	pojected variances have no meaning													

Benzene Health Research Consortium
API Administration 2Q07 Financial Report

	O	P	Q	R	S	T	U	V	W	X
1			2006				2007			
2	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	TOTALS
3										
4	25,000	15,000	10,000	15,000	15,000	15,000	15,000	20,000	20,000	516,865
5	23,056	12,470	16,876	25,349	19,194	10,957	15,651	-	-	514,703
6	1,944	2,530	(6,876)	(10,349)	(4,194)	4,043	(651)	20,000	20,000	165,681
7	(2,189)	341	(6,535)	(16,885)	(21,078)	(17,035)	(17,686)	2,314	22,314	22,314
8										
9	3,000	1,800	1,200	1,800	1,800	1,800	1,800	2,400	2,400	64,402
10	2,883	1,559	2,109	3,169	2,399	1,370	1,956	-	-	63,967
11	117	241	(909)	(1,369)	(599)	430	(156)	2,400	2,400	21,474
12	(573)	(332)	(1,241)	(2,610)	(3,209)	(2,779)	(2,935)	(535)	1,865	1,865
13										
14	5,000	1,000	1,000	1,000	1,000	1,000	1,000	10,000	1,000	64,952
15	6,931	22	1,201	1,520	1,080	-	-	-	-	36,133
16	(1,931)	978	(201)	(520)	(80)	1,000	1,000	10,000	1,000	28,819
17	(567)	411	210	(310)	(391)	609	1,609	11,609	12,609	12,609
18										
19	5,000	1,000	1,000	5,000	1,000	1,000	1,000	10,000	6,450	67,357
20	1,747	533	583	661	1,368	1,597	1,733	-	-	94,486
21	3,253	467	417	4,339	(368)	(597)	(733)	10,000	6,450	30,825
22	3,360	3,827	4,245	8,584	8,215	7,618	6,886	16,886	23,336	23,336
23										
24	7,000	4,200	2,800	4,200	4,200	4,200	4,200	5,600	5,600	154,925
25	6,456	3,492	4,725	7,098	5,374	3,068	4,382	-	-	146,778
26	544	708	(1,925)	(2,898)	(1,174)	1,132	(182)	5,600	5,600	8,147
27	(613)	95	(1,830)	(4,728)	(5,902)	(4,770)	(4,952)	648	6,248	6,248
28										
29	14,000	12,500	14,000	14,000	14,000	18,000	18,000	18,000	18,000	441,300
30	6,999	12,500	12,500	12,500	12,500	13,750	13,750	-	-	361,096
31	7,001	-	1,500	1,500	1,500	4,250	4,250	18,000	18,000	80,204
32	19,003	19,003	20,503	22,003	23,503	27,753	32,003	50,003	68,003	68,003
33										
34	4,500	5,000	5,000	5,000	5,000	6,000	6,000	6,000	6,000	135,404
35	4,500	-	-	-	-	-	-	-	-	53,458
36	-	5,000	5,000	5,000	5,000	6,000	6,000	6,000	6,000	81,946
37	-	5,000	10,000	15,000	20,000	26,000	32,000	38,000	44,000	44,000
38			2006				2007			
39	63,500	40,500	35,000	46,000	42,000	47,000	47,000	72,000	59,450	1,445,205
40	52,572	30,576	37,995	50,296	41,916	30,741	37,472	-	-	923,832
41	10,928	9,924	(2,995)	(4,296)	84	16,259	9,528	72,000	59,450	450,028
42	18,421	28,345	25,351	21,054	21,139	37,397	46,925	118,925	178,375	178,375
43			2006				2007			
44	1,056,255	1,096,755	#####	1,177,755	1,219,755	1,266,755	1,313,755	1,385,755	1,445,205	1,445,205
45	1,041,625	1,072,201	#####	1,160,492	1,202,407	1,233,149	1,270,621	1,270,621	1,270,621	1,270,621
46	14,630	24,554	21,560	17,263	17,348	33,606	43,134	115,134	174,584	174,584
47										
48										
49										
50										

Benzene Health Research Consortium
Exposure Assess 2Q07 Financial Report

	A	B	C	D	E	F	G	H	I	J
1	Exposure assessment (X8111)	2006				2007				TOTALS
2	Cost Centers	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3	Herrick									
4	Budgeted	-	-	-	20,000	15,000	15,000	6,000	-	56,000
5	Actual expense	-	-	-	12,324	-	7,862	-	-	20,186
6	Current Variance	-	-	-	7,676	15,000	7,138	6,000	-	35,814
7	Cumm Variance	-	-	-	7,676	22,676	29,814	35,814	35,814	35,814
8	Cherrie/IOM									
9	Budgeted	-	-	-	20,000	15,000	15,000	3,000	-	53,000
10	Actual expense	-	-	-	-	4,583	8,877	-	-	13,460
11	Current Variance	-	-	-	20,000	10,417	6,123	3,000	-	39,540
12	Cumm Variance	-	-	-	20,000	30,417	36,540	39,540	39,540	39,540
13	TOTALS	2006				2007				
14	Budgeted	-	-	-	40,000	30,000	30,000	9,000	-	109,000
15	Actual expense	-	-	-	12,324	4,583	16,739	-	-	33,646
16	Current Variance	-	-	-	27,676	25,417	13,261	9,000	-	75,354
17	Cummulative Variance	-	-	-	27,676	53,093	66,354	75,354	75,354	75,354
18	CUMULATIVE TOTALS	2006				2007				
19	Budgeted	-	-	-	40,000	70,000	100,000	109,000	109,000	
20	Expense	-	-	-	12,324					
21	Variance	-	-	-	27,676	53,093	66,354	75,354	75,354	
22										
23	rdw 10/19/06									
24	RT 8/1/2007									

	A	B	C	D	E	F	G	H	I	J	K	L	M	N
1	Cinpathogen (X8112)	2006				2007				2008				TOTALS
2	Cost Centers	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3														
4	Budgeted	-	-	-	-	-	2,100,000	-	1,275,000					3,375,000
5	Actual expense	-	-	-	-	-	2,100,000	-	-					2,100,000
6	Current Variance	-	-	-	-	-	-	-	1,275,000					1,275,000
7	Cumm Variance	-	-	-	-	-	-	-	1,275,000					1,275,000
8														
9	Budgeted	-	-	-	-	-	-	-	-					-
10	Actual expense	-	-	-	-	-	-	-	-					-
11	Current Variance	-	-	-	-	-	-	-	-					-
12	Cumm Variance	-	-	-	-	-	-	-	-					-
13	TOTALS	2006				2007								
14	Budgeted	-	-	-	-	-	2,100,000	-	1,275,000					3,375,000
15	Actual expense	-	-	-	-	-	2,100,000	-	-					2,100,000
16	Current Variance	-	-	-	-	-	-	-	1,275,000					1,275,000
17	Cummulative Variance	-	-	-	-	-	-	-	1,275,000					1,275,000
18	CUMULATIVE TOTALS	2006				2007								
19	Budgeted	-	-	-	-	-	2,100,000	2,100,000	3,375,000					
20	Expense	-	-	-	-	-	-	-	-					
21	Variance	-	-	-	-	-	-	-	1,275,000					
22														
23														
24	RT 8/1/2007													

Benzene Health Research Consortium
Contingency Fund 2Q07 Financial Report

	A	B
1		
2		2003*
3	Contingency Funds	4th Qtr.
4		
5	Current quarter expense/commitment	101,473
6	Total spent/committed	101,473
7	Amount remaining	288,799
8		
9		
10		
11	EXPENSE DETAIL	
12		
13	Reallocations from UCHSC	48,839
14	Reallocations from AHS	52,634
15	Histopath Review - J. Bennett	
16	Non-contract**	
17	Newfields (Kreiger)	
18	Committed on contract	-
19	Current quarter expense	-
20	Remaining funds	-
21	* Line item created 4Q03	
22	** to be reprogrammed as API expense in 3Q05	
23	LT 8/3/05	
24	RT 7/19/06	4Q03 Adjustment - per Technical Committee, transfer \$48,839 from UCHSC expense detail to contingency because expenses not part of UCHS
25	DRAFT	
26		
27		
28		
29		AHS - expense transfer of \$52,634 from AHS expense detail to contingency because expenses not part of AHS full study budget

Benzene Health Research Consortium
Contingency Fund 2Q07 Financial Report

	C	D	E	F	G	H
1						
2	2004					2005
3	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.
4						
5	-	-	-	3,000	50,296	422
6	101,473	101,473	101,473	104,473	154,769	155,191
7	188,799	188,799	188,799	485,799	435,503	435,081
8						
9						
10						
11						
12						
13						
14						
15				3,000	3,000	
16					496	422
17						
18	-	-	-	-	46,800	46,800
19	-	-	-	-	-	7,058
20	-	-	-	-	46,800	39,742
21						
22						Contingency
23						Total program budget as of 2Q07
24						spent/committed as of 2Q07
25						Remaining
26	1. June 2001 \$25K grant to UCHSC; seed money exhausted (API & sponsor), expense not included in final grant cost estimate					
27	2. \$3600 IRB fees to U of CO (this will be a yearly fee, since IRB must review at least once per year)					
28	3. 2002 invoice (\$20,239) from EMBSI for final feasibility study work (very late billing to API)					
29						

Benzene Health Research Consortium
Contingency Fund 2Q07 Financial Report

	I	J	K	L	M	N	O	P	Q	R
1										
2	2006						2007			
3	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.
4										
5	-	1,200	-	-	-	-	-	-	-	-
6	155,191	156,391	156,391	156,391	156,391	156,391	156,391	156,391	156,391	156,391
7	850,695	850,695	850,695	850,695	840,900	798,907	814,988	1,570,593	1,570,593	1,570,593
8										
9										
10										
11										
12										
13										
14										
15										
16		1,200								
17										
18	39,742	39,742	-	-	-	-	-	-	-	-
19	-	288	-	-	-	-	-	-	-	-
20	39,742	39,454	-	-	-	-	-	-	-	-
21										
22	y Summary									
23			1,570,593							
24			156,391							
25			1,414,201							
26										
27										
28										
29										

Benzene Health Research Consortium
Income 2Q07 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
1		2000	2001	2002		2003			2004				2005				2006	
2		1st - 4th Qtr.	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.
3	INCOME																	
4	Sponsor Payments	60,000	2,105,509	8,355,629	448,024	-	4,259,965	1,485,875	-	-	-	1,096,000	365,334	2,933,879	674,000	-	1,914,080	-
5	API Interest	246	7,623	11,817	-	3,186	5,276	-	6,746	6,506	9,292	-	6,809	14,899	54,727	-	20,211	16,582
6	UCHSC Interest	-	-	-	-	-	-	-	-	-	-	-	-	61,009				15,192
7	TOTALS																	
8	Reporting Period	60,246	2,113,132	8,367,446	448,024	3,186	4,265,241	1,485,875	6,746	6,506	9,292	1,096,000	372,143	3,009,787	728,727	-	1,934,291	31,774
9	Cumulative	60,246	2,173,378	10,540,824	10,988,848	10,992,034	15,257,275	16,743,149	16,749,895	16,756,401	16,765,693	17,861,693	18,233,836	21,243,623	21,972,350	21,972,350	23,906,641	23,938,415
10																		
11																		
12	projected income																	
13																		
14	LT 8/23/05	DRAFT															23,698,294	
15	rdw 10/19/06																	
16	RT 8/1/2007																	
17																		
18																		

Benzene Health Research Consortium
Income 2Q07 Financial Report

	S	T	U	V	W	X	Y	Z	AA	AB
1										
2	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	TOTALS
3										
4	4,916,018	-	3,119,412	1,039,804						32,773,528
5	56,081	-	46,996		20,000		10,000		5,000	301,996
6										76,202
7										
8	4,972,098	-	3,166,408	1,039,804	20,000					33,136,725
9	28,910,513	28,910,513	32,076,921	33,116,725	33,136,725					
10										
11										
12										
13										
14										
15										
16										
17										
18										

**Benzene Health Research Consortium
Sponsor Invoice Detail 2Q07 Financial Report**

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	
1					2001			2002 (1st - 2nd Qtr.)			2002 (3rd - 4th Qtr.)			2003				
2	Company Name	(Seed Money)	Inv. #	Date Paid	22-Aug-01	Inv. #	Date Paid	9-Jan-02	Inv. #	Date Paid	27-Aug-02	Inv. #	Date Paid	23-Sep-03	Inv. #	Date Paid	27-Jan-05	
3	BP	\$15,000	522922	8-Nov-00	\$768,941	529301	4-Oct-01	\$806,441	532263	22-Feb-02	\$1,344,069	535033	11-Oct-02	\$1,431,041.00	544951	4-Dec-03	\$2,568,545.00	
4		\$22,500	528453	19-Jun-01							\$112,008		2-Oct-02					
5																		
6	Chevron	\$15,000	522923	7-Nov-00	\$522,627	529302	9-Oct-01	\$537,627	532244	22-Feb-02	\$896,046	535034	5-Nov-02	\$1,028,700.00	544953	19-Nov-03	\$365,334.00	
7																		
8																		
9	ConocoPhillips	\$15,000	522924	31-Oct-00	\$246,314	529309	17-Sep-01	\$268,814	532245	16-Jan-02	\$448,023	535035	26-Sep-02	\$514,349.00	544954	27-Oct-03	\$548,000.00	
10		\$7,500	528574	31-Jul-01														
11																		
12	ExxonMobil	\$0	523540					\$1,612,882	532246		\$1,344,069	535036	13-Sep-02	\$1,543,049.00	544956		\$548,000.00	
13								\$806,441		23-Jan-02				\$771,524.50		3-Oct-03	\$274,000.00	
14								\$806,441		11-Feb-02				\$771,524.50		22-Mar-04		
15																		
16	Shell	\$15,000	523054	24-Oct-00	\$507,627	529305	25-Sep-01	\$537,627	532247	7-Feb-02	\$896,046	535037		\$1,028,700.00	544958		\$365,334.00	
17		\$15,000	528333	15-May-01							\$448,023		25-Sep-02	\$514,350		28 Oct 03		
18											\$448,023		10-Feb-03	\$514,350		14 Jan 04		
19																		
20	Marathon	\$15,000	528541	14-Aug-01								Marathon Ashland		\$150,000	548582	20-Jan-04	\$0	
21												Marathon Oil		\$50,000	548581	3-Feb-04		
22	Total	\$120,000			\$2,045,509			\$5,376,273			\$5,936,307			\$8,317,588.00			\$4,669,213.00	
23																		
24																		
25		Invoicing Amendment No. 3									Projected Invoicing Amendment No. 4							
26		2006			2007			Projected			2007			2008			Projected	
27	Company Name	Amount	Inv. #	Date Paid	Amount	Inv. #	Date Paid	TOTALS			Company Name	Amount	Inv. #	Date Paid	Amount	Inv. #	Date Paid	TOTALS
28	BP	\$0.00			\$0.00			\$7,068,545			BP	\$2,481,311		1-Dec-06	\$0			\$9,549,856
29																		
30	Chevron	\$911,959.00	575044	10-Oct-06	\$435,071.00	581762	30-Apr-07	\$4,712,364			Chevron							\$6,366,572
31												\$1,039,804	591129		\$614,404			
32	ConocoPhillips	\$308,182	575045	19-Jun-06	\$0.00			\$2,356,182			ConocoPhillips	\$519,902	591131	30-Jun-07	\$307,202			\$3,183,286
33																		
34	ExxonMobil	\$1,093,939	575042	31-May-06	\$652,606.00	581763	28-Feb-07	\$7,068,545			ExxonMobil							\$9,549,857
35												\$1,559,706	591130	30-Jun-07	\$921,606			
36																		
37	Shell	\$400,000.00	571301	3-Mar-06	\$435,071.00	581764	31-Jan-07				Shell							
38		\$511,959	575043	2-Jun-06				\$4,712,364				\$1,039,804	591128	30-Jun-07	\$614,404			\$6,366,572
39																		
40	Marathon	\$0			\$0			\$215,000			Marathon	\$0			\$0			\$215,000
41																		
42	Total	\$3,226,039			\$1,522,748			\$26,133,000			Total	\$6,640,527			\$2,457,616			\$35,231,143
43																		
44																		
45	LT 8/18/05		DRAFT															
46	RT 8/1/2007																	

**Benzene Health Research Consortium
Sponsor Invoice Detail 2Q07 Financial Report**

	R	S	T	U	V	W	X	Y	Z	AA	AB	AC
1	005		2006			2007				2008		PAID
2	Inv. #	Date Paid	4-Apr-06	Inv. #	Date Paid		Inv. #	Date Paid		Inv. #	Date Paid	TOTALS
3	563928	11-Jul-05	\$2,481,311.00			\$0.00			\$0			
4												\$7,068,545
5												
6	560056	19-Jul-05	\$911,959.00	575044	10-Oct-06	\$435,071.00	581762	30-Apr-07				\$4,712,364
7						\$1,039,804.00	591129					
8												
9	560057	18-Mar-05	\$308,182.00	575045	19-Jun-06	\$519,902.00	591131	30-Jun-07				\$2,876,084
10												
11												
12	560058	17-Feb-05	\$1,093,939.00	575042	31-May-06	\$652,606.00	581763	28-Feb-07				\$8,628,251
13	564774	27-Dec-05				\$1,559,706.00	591130	30-Jun-07				
14												
15												
16	560059	28-Apr-05	\$400,000.00	571301	3-Mar-06	\$435,071.00	581764	31-Jan-07				
17			\$511,959	575043	2-Jun-06	\$1,039,804.00	591128	30-Jun-07				\$5,752,168
18												
19												
20			\$0			\$0			\$0			\$215,000
21												
22			\$5,707,350.00			\$5,681,964.00						\$29,252,412
23												
24												
25												
26												
27												
28												
29												
30												26133
31												25859
32												274
33												
34												
35												
36												
37												
38												
39												
40												
41												
42												
43												
44												
45												
46												

Benzene Health Research Consortium
Sponsor Payment Detail 2Q07 Financial Report

	A	B	C	D	E	F	G
1	ID	CompanyName	PaymentDate	PaymentAmount	TOTALS		
2	19982	Shell Chemical	10/24/2000	\$ 15,000.00			
3	20086	ConocoPhillips	10/31/2000	\$ 15,000.00			
4	20972	ChevronTexaco	11/7/2000	\$ 15,000.00	yr 2000		
5	20239	BP International Limited	11/8/2000	\$ 15,000.00	\$ 60,000.00		
6	28285	Shell Chemical	5/15/2001	\$ 15,000.00			
7	28929	BP International Ltd	6/19/2001	\$ 22,500.00			
8	29861	ConocoPhillips	7/31/2001	\$ 7,500.00			
9	30179	Marathon Ashland Petroleum, LLC.	8/14/2001	\$ 15,000.00			
10	30853	ConocoPhillips	9/17/2001	\$ 246,314.00			
11	31000	Shell Chemical	9/25/2001	\$ 507,627.00			
12	31141	BP p.l.c.	10/4/2001	\$ 768,941.00	yr 2001		
13	31179	ChevronTexaco	10/9/2001	\$ 522,627.00	\$ 2,105,509.00		
14	33206	ConocoPhillips	1/16/2002	\$ 268,814.00			
15	34334	ExxonMobil Research and Engineering	1/23/2002	\$ 806,441.00			
16	34823	Shell Chemical	2/7/2002	\$ 537,627.00			
17	34889	ExxonMobil Research and Engineering	2/11/2002	\$ 806,441.00			
18	35200	ChevronTexaco	2/22/2002	\$ 537,627.00			
19	35207	BP p.l.c.	2/22/2002	\$ 806,441.00			
20	38625	ExxonMobil	9/13/2002	\$ 1,344,069.00			
21	38748	Shell Chemical	9/25/2002	\$ 448,023.00			
22	38779	ConocoPhillips	9/26/2002	\$ 448,023.00			
23	39101	BP p.l.c.	10/2/2002	\$ 112,008.00			
24	39214	BP p.l.c.	10/11/2002	\$ 1,344,069.00	yr 2002		
25	39493	ChevronTexaco	11/5/2002	\$ 896,046.00	\$ 8,355,629.00		
26	42934	American Petroleum Institute	1/17/2003	\$ 1.09	1+2Q03		
27	44094	Shell Chemical	2/10/2003	\$ 448,023.00	\$ 448,024.09		
28	51153	ExxonMobil	10/3/2003	\$ 771,524.50			
29	51869	ConocoPhillips	10/27/2003	\$ 514,349.00			
30	51891	Shell Chemical	10/28/2003	\$ 514,350.00			
31	52332	ChevronTexaco	11/19/2003	\$ 1,028,700.00	4Q03		
32	52633	BP p.l.c.	12/4/2003	\$ 1,431,041.00	\$ 4,259,964.50		
33	54618	Marathon Ashland Petroleum, LLC.	1/20/2004	\$ 150,000.00			
34	54472	Shell Chemical	1/13/2004	\$ 514,350.00			
35	55187	Marathon Oil Company	2/3/2004	\$ 50,000.00	1Q04		
36	57362	ExxonMobil	3/22/2004	\$ 771,524.50	\$ 1,485,874.50		
37	560057	ConocoPhillips	3/18/2005	\$ 548,000.00	1Q05		
38	560058	ExxonMobil	2/17/2005	\$ 548,000.00	\$ 1,096,000.00		
39	560059	Shell Chemical	4/28/2005	\$ 365,334.00	2Q05		
40					\$ 365,334.00		
41	563928	BP p.l.c.	7/11/2005	\$ 2,568,545.00	3Q05		
42	560056	Chevron	7/19/2005	\$ 365,334.00	\$ 2,933,879.00		
43	79001	ExxonMobil	12/27/2005	\$ 274,000.00	4Q05		
44					\$ 274,000.00		
45					1Q06		
46	571301	Shell Chemical	3/3/2006	\$ 400,000.00	\$ 400,000.00		
47	575042	ExxonMobil	5/31/2006	\$ 1,093,939.00	2Q06		
48	575045	Shell Chemical	6/2/2006	\$ 511,959.00			
49	575043	ConocoPhillips	6/21/2006	\$ 308,182.00	\$ 1,914,080.00		
50					4Q06		
51	575044	Chevron	10/10/2006	\$ 911,959.00	\$ 3,393,270.00		
52	none	BP p.l.c.	Dec-06	\$ 2,481,311.00			
53	581762	Chevron	1/31/2007	\$ 435,071.00	1Q07		
54	581763	ExxonMobil	2/28/2007	\$ 652,606.00	\$ 1,087,677.00		
55	581764	Shell Chemical	4/30/2007	\$ 435,071.00	2Q07		
56	591128	Shell Chemical	6/30/2007	\$ 1,039,804.00			
57	591130	ExxonMobil	6/30/2007	\$ 1,559,706.00			

Benzene Health Research Consortium
Sponsor Payment Detail 2Q07 Financial Report

	A	B	C	D	E	F	G
58	591131	ConocoPhillips	6/30/2007	\$ 519,902.00	\$ 3,554,483.00		
59							
60				\$ 31,733,724.09			\$31,733,724.09
61			(note - does not include interest income)				
62	LT 8/3/05	DRAFT					
63	RT 8/1/2007						

BHRC Sponsor Payments
Organized by Sponsor Company - 2Q07

	A	B	C	D	E
1	Company	Date Paid	Amount		
2	American Petroleum Institute	1/17/2003	\$ 1.09	(I am trying to get this \$1.09 removed from the books)	
3	BP International Limited	11/8/2000	\$ 15,000.00		
4	BP International Ltd	6/19/2001	\$ 22,500.00		
5	BP p.l.c.	10/4/2001	\$ 768,941.00		
6	BP p.l.c.	2/22/2002	\$ 806,441.00		
7	BP p.l.c.	10/2/2002	\$ 112,008.00		
8	BP p.l.c.	10/11/2002	\$ 1,344,069.00		
9	BP p.l.c.	12/4/2003	\$ 1,431,041.00	BP Total	
10	BP p.l.c.	7/11/2005	\$ 2,568,545.00	\$ 7,068,545.00	
11	BP p.l.c.	12/1/2006	\$ 2,481,311.00		
12	ChevronTexaco	11/7/2000	\$ 15,000.00		
13	ChevronTexaco	10/9/2001	\$ 522,627.00		
14	ChevronTexaco	2/22/2002	\$ 537,627.00		
15	ChevronTexaco	11/5/2002	\$ 896,046.00		
16	ChevronTexaco	11/19/2003	\$ 1,028,700.00		
17	ChevronTexaco	7/19/2005	\$ 365,334.00	ChevronTexaco Total	
18	Chevron	10/10/2006	\$ 911,959.00		
19	Chevron	4/30/2007	\$ 435,071.00	\$ 4,712,364.00	
20	ConocoPhillips	10/31/2000	\$ 15,000.00		
21	ConocoPhillips	7/31/2001	\$ 7,500.00		
22	ConocoPhillips	9/17/2001	\$ 246,314.00		
23	ConocoPhillips	1/16/2002	\$ 268,814.00		
24	ConocoPhillips	9/26/2002	\$ 448,023.00		
25	ConocoPhillips	10/27/2003	\$ 514,349.00	ConocoPhillips Total	
26	ConocoPhillips	3/18/2005	\$ 548,000.00		
27	ConocoPhillips	6/19/2006	\$ 308,182.00		
28	ConocoPhillips	6/30/2007	\$ 519,902.00	\$ 2,876,084.00	
29	ExxonMobil Research and Engineering	1/23/2002	\$ 806,441.00		
30	ExxonMobil Research and Engineering	2/11/2002	\$ 806,441.00		
31	ExxonMobil	9/13/2002	\$ 1,344,069.00		
32	ExxonMobil	10/3/2003	\$ 771,524.50		
33	ExxonMobil	3/22/2004	\$ 771,524.50	ExxonMobil Total	
34	ExxonMobil	2/17/2005	\$ 548,000.00		
35	ExxonMobil	12/27/2005	\$ 274,000.00		
36	ExxonMobil	5/31/2006	\$ 1,093,939.00		
37	ExxonMobil	2/28/2007	\$ 652,606.00		
38	ExxonMobil	6/30/2007	\$ 1,559,706.00	\$ 8,628,251.00	
39	Marathon Ashland Petroleum, LLC.	8/14/2001	\$ 15,000.00		
40	Marathon Ashland Petroleum, LLC.	1/20/2004	\$ 150,000.00	Marathon Ashland Total	
41	Marathon Oil Company	2/3/2004	\$ 50,000.00	\$ 215,000.00	
42	Shell Chemical	10/24/2000	\$ 15,000.00		
43	Shell Chemical	5/15/2001	\$ 15,000.00		
44	Shell Chemical	9/25/2001	\$ 507,627.00		
45	Shell Chemical	2/7/2002	\$ 537,627.00		
46	Shell Chemical	9/25/2002	\$ 448,023.00		
47	Shell Chemical	2/10/2003	\$ 448,023.00		
48	Shell Chemical	10/28/2003	\$ 514,350.00		
49	Shell Chemical	1/13/2004	\$ 514,350.00	Shell Chemical Total	
50	Shell Chemical	4/28/2005	\$ 365,334.00		

BHRC Sponsor Payments
Organized by Sponsor Company - 2Q07

	A	B	C	D	E
51	Shell Chemical	3/3/2006	\$ 400,000.00		
52	Shell Chemical	6/2/2006	\$ 511,959.00		
53	Shell Chemical	1/31/2007	\$ 435,071.00		
54	Shell Chemical	4/30/2007	\$ 1,039,804.00	\$ 5,752,168.00	
55			\$ 31,733,724.09		
56	LT 8/3/05	DRAFT			
57	RT 8/1/07				